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For the majority of assays currently performed, fluorescent or colorimetric 
chemical labels are commonly attached to the molecules under study so that they may be 
readily visualized [1-3].  The methods of using labels to track biomolecular binding 
events are very sensitive and effective, and are employed as standardized assay protocol 
across research labs worldwide.  However, using labels induces experimental 
uncertainties due to the effect of the label on molecular conformation, active binding sites, 
or inability to find an appropriate label that functions equivalently for all molecules in an 
experiment [4].  Therefore, the ability to perform highly sensitive biochemical detection 
without the use of fluorescent labels would further simplify assay protocols and would 
provide quantitative kinetic data, while removing experimental artifacts from fluorescent 
quenching, shelf-life, and background fluorescence phenomena [5]. 
In view of the advantages mentioned above, the study and development of optical 
label-free sensor technologies have been undertaken here.  In general, label-free photonic 
crystal (PC) biosensors and metal nanodome array surface-enhanced Raman scattering 
(SERS) substrates, both of which are fabricated by nanoreplica molding process, have 
been used as the method to attack the problem.  Chapter 1 shows the work on PC label-
free biosensor incorporated microfluidic network for bioassay performance enhancement 
and kinetic reaction rate constant determination.  Chapter 2 describes the work on 
theoretical and experimental comparison of label-free biosensing in microplate, 
microfluidic, and spot-based affinity capture assays.  Chapter 3 shows the work on 
integration of PC biosensor with actuate-to-open valve microfluidic chip for pL-volume 
combinatorial mixing and screening application.  In Chapter 4, the development and 
 iii 
characterization of SERS nanodome array is shown.  Lastly, Chapter 5 describes SERS 
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CHAPTER 1: LABEL-FREE PHOTONIC CRYSTAL BIOSENSOR 
INTEGRATED MICROFLUIDIC CHIP FOR DETERMINATION OF KINETIC 
REACTION RATE CONSTANTS 
1.1 Introduction 
The ability to perform biochemical and cellular analysis using small reagent 
volumes and high measurement throughput has been one of the driving forces behind the 
development of microfluidic lab-on-a-chip (LOC) devices and micro-total-analysis 
systems (µTAS) [6-8].  Often, such systems are produced using microfabrication methods 
upon glass or silicon substrates with custom-designed interfaces that allow microliter 
quantities of reagents to be introduced into a system of microfluidic channels.  However, 
within the field of pharmaceutical discovery and laboratory-based diagnostic assays, a 
great deal of liquid handling infrastructure currently exists for interfacing with standard 
96, 384, and (more recently) 1536-well microplates.  For this reason, it is desirable for a 
label-free biosensing system to easily integrate with these standard formats to enable high 
throughput in a single-use disposable format.  This requirement has driven the 
commercial adoption of photonic crystal (PC) biosensor microplates for applications in 
pharmaceutical high throughput screening for measuring protein-protein interactions [9-
12], protein-small molecule interactions [13], cell-based assays [14, 15], and cell-drug 
interactions [16].  While label-free optical biosensors embedded within the bottom 
surface of microplate wells offer a convenient high throughput detection system, the 
kinetics that drive detection of biomolecules to attach to the sensor surface is based 
mainly upon diffusion.  Many publications have demonstrated the efficacy of biosensors 
interfaced with microfluidic channels as a means for obtaining detection kinetics that are 
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limited by chemical reaction rates.  These can serve as a rapid and sensitive means for 
characterizing ligand-analyte binding affinity constants through the rate of change of 
detected biosensor signal [17-21].  
 Recently, the co-fabrication of PC biosensors with a network of microfluidic 
channels was demonstrated using a silicon “master” template wafer that contains both the 
micrometer-scale surface structure for microfluidic channels and the nanometer-scale 
surface features for the PC biosensor structure.  The resulting PC sensors and fluid 
channels were automatically self-aligned, and were fabricated over a 3 × 5 inch area on 
flexible plastic substrates for integration with a standard 96-well microplate.  A simple 
valveless control scheme was also demonstrated in which some wells were designated as 
“control” wells.  The control wells were used for introducing capture molecules and 
analytes through the microfluidic channels for real-time monitoring of up to 11 
biochemical binding interactions in parallel with a high resolution label-free imaging 
detection instrument [22].  With the device, reduction in the end-point binding assay time 
was achieved, but kinetic analysis could not be effectively performed with the use of a 
long flow channel length (64 mm), which was required to bring analytes from the 
“analyte” microplate wells to the central measurement point.  To ensure equal flow rate 
for a pneumatic pressure applied equally to all “analyte” wells, serpentine flow paths 
were implemented for wells with closest proximity to the measurement point.  Despite 
these efforts, the previously reported chip exhibited flow rate differences between analyte 
flow channels, and limitations on the maximum achievable fluid flow rate. 
In this chapter, a PC biosensor integrated microfluidic chip compatible with a 
384-well microplate format is demonstrated.  The device structure enables low volume 
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kinetic analysis of protein-protein interactions through 5 analyte flow channels with a 
single control point and offers higher assay density.  It is important to note that the 384-
well fluid channel microplate reported in this chapter requires significantly shorter 
analyte travel distance from the inlet region to the PC detection region, compared to the 
96-well microplate sensor format reported previously, in which kinetic analysis could not 
be performed effectively.  This is important especially for accurate kinetic analysis of low 
analyte concentrations because short analyte travel distance enables very low flow 
latency and helps mitigate the effects of analyte molecule depletion through attachment to 
the channel walls before reaching the detection region.  The resulting biosensor 
microfluidic microplate and detection instrument are capable of rapid and high 
throughput characterization of biochemical binding constants in a format that is 
compatible with existing 384-well microplate liquid handling systems. 
 
1.2 Materials and Methods 
The photonic crystal (PC) shown in Figure 1.1 is a nanostructure comprising a 
periodically modulated low refractive index UV cured polymer linear periodic grating 
coated with a high refractive index dielectric layer of titanium dioxide (TiO2).  The 
device is designed to reflect only a narrow band of wavelengths with 100% efficiency 
when illuminated with white light at normal incidence [23].  The resonant reflection is 
due to evanescent diffracted orders coupling to modes of an effective high refractive 
index layer, which are then re-radiated through diffraction in-phase with the reflected 
zeroth-order wave [24].  A positive shift of the reflected peak wavelength value (PWV) 
indicates adsorption of material on the sensor surface.  Previously, PC optical biosensors 
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have been fabricated on continuous sheets of plastic film using a process in which the 
periodic surface structure is replica molded directly from a silicon master wafer using a 
UV-cured polymer material [9-12, 14, 15].  The use of a continuous, roll-based, high-
throughput replication process enables low-cost mass-production of large surface-area 
devices for single-use disposable products, capable of integration into microplates and 
microarray slides.  
 
Figure 1.1  Schematic cross section diagram of the photonic crystal biosensor. 
 
1.2.1 PC sensor integrated microfluidic chip 
A schematic of the sensor-integrated microfluidic chip is shown at the top of 
Figure 1.2.  The flow channels and the PC biosensor are co-fabricated and self-aligned on 
a single sheet of flexible plastic.  A planar plastic cover is then applied over the flow 
channels to form the upper surface, and to provide holes for fluid access. The 
microfluidic network assembly is attached with adhesive to a bottomless 384-well 
microplate, where it forms the bottom surface.  The holes on the fluid chip are arranged 
so that each microplate well has access to the microfluidic network through one hole.  As 
shown in Figure 1.2, the fluid channels from 5 “analyte” wells are gathered to a single 
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detection region, where all 5 channels may be monitored at once.  A “common” well 
serves as an access point for introduction of reagents that are identical for all of the flow 
channels. The common well also serves as a means for applying positive or negative 
pressure that will drive fluid from the common well into the flow channels, or to pull 
fluid from the 5 analyte wells at the same rate.  The bends in the channel have minimal 
effect on the overall flow rate of the channels and no flow latency between the channels 
was observed. 
 
Figure 1.2  Schematic of the PC biosensor integrated microfluidic assay chip with the high resolution 
imaging detection instrument. 
 
1.2.2  Device fabrication 
A room-temperature, low-force replica-molding process utilizing a patterned 
silicon master and a UV-curable polymer (Gelest, Inc.) is used to fabricate the devices 
[25].  The fabrication method accurately produces sub-micron features for the PC 
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structure, while at the same time generating > 10 µm features for the microfluidic 
channels in a single molding step. 
First, a silicon wafer was patterned with a 550 nm period 1-dimensional linear 
grating structure using deep-UV lithography and reactive ion etching to a depth of 170 
nm.  The fluid channels were then patterned onto the same silicon wafer using 
conventional contact lithography and deep reactive ion etching to a depth of 30 µm.  As a 
result of the above processing steps, a negative pattern template of microfluidic channels 
incorporating a sub-micron linear grating was fabricated.  The completed silicon master 
was subsequently treated with dimethyl dichlorosilane (GE Healthcare) to promote clean 
release of the replica from the master. 
Next, the master wafer pattern was replicated onto a 250 µm thick flexible 
polyethylene terephthalate (PET) substrate (plastic substrate in Figure 1.1) by distributing 
a layer of liquid UV curable polymer between the silicon wafer and the PET substrate 
where the liquid polymer conforms to the shape of the features on the wafer.  The liquid 
polymer was then cured to a solid state by exposure to UV light at room temperature and 
was subsequently released from the wafer by peeling away the PET, resulting in a 
polymer replica of the silicon wafer structure adhering to the PET sheet.  The sensor 
structure was completed by depositing 130 nm of titanium dioxide (TiO2) on the replica 
surface using electron beam evaporation.  For the high index layer of PC sensor structure, 
any dielectric material that has similar refractive index (n = 2.3) with low optical loss and 
is inert to biochemical reagents or reactions could also be used.  The SEM images of the 




Figure 1.3  SEM images of an open microfluidic channel embedded with the PC biosensor. 
 
The open microfluidic channels were sealed by a separate PET sheet with die-
punched 1.6 mm diameter inlet/outlet holes in a pattern corresponding to the locations of 
the wells of a standard 384-well microplate using a layer of double sided optically clear 
laminating adhesive film (3M).  To complete the packaging, the fabricated polymer 
microfluidic network assembly was then attached to a bottomless 384-well microplate 
using an adhesive.  The seal provided by the adhesive was very effective and no leakage 
of fluids occurred. 
 
1.2.3 Detection instrument 
A schematic of the biosensor imaging instrument is shown in the bottom of Figure 
1.2.  White light illuminates the sensor at normal incidence and polarized perpendicular 
to the sensor grating lines.  The reflected light is directed through a beam splitter and an 
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imaging lens to a narrow slit aperture at the input of the imaging spectrometer.  Using 
this method, reflected light is collected from a line on the sensor surface, where the width 
of the imaged line is determined by the width of the entrance slit of the spectrometer.  
The imaging spectrometer contains a 2-dimensional CCD chip (Acton Research) with 
2048 × 512 pixels, in which the line image through the slit is divided into 512 pixels and 
a spectrum with a resolution of 2048 wavelength data points is acquired for each of the 
512 pixels imaged.  With a spectral measurement range of 830 to 890 nm, the detection 
instrument sampling interval is 0.0293 nm.  Further details on the detection instrument 
performance specifications can be found in [26].  Upon peak-finding analysis of all 512 
spectra, the PWV for each of the 512 pixels is determined, and thus a line of 512 pixels is 
generated for the PWV image of the sensor.   
Based on the PWV imaging mechanism described above, the detection instrument 
is capable of operating in two different modes: kinetic mode and imaging mode.  For 
kinetic measurements (measuring ∆PWV as a function of time), a motorized stage 
positions the sensor so that the image line remains fixed upon a single location that 
intersects 5 flow channels (see Figure 1.2) while the PWV of the PC is measured at fixed 
time intervals.  The measurement interval can be designated by software, where the lower 
limit (~0.2 sec per measurement) is determined by the integration time of the CCD chip, 
data analysis/routing time, and processing load on the computer.  For the imaging mode 
(generating 2-dimensional spatial PWV image of the sensor) however, the motorized 
stage translates the sensor in a direction perpendicular to the image line in small 
increments, constructing a spatial map of the PC PWV.  By this technique a series of 
lines are assembled into an image through a software program and a large area can be 
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scanned in a serpentine tiled fashion.  The PWV pixel resolution, or the line width of the 
imaged line for this work, was 22.3 µm.  The detection instrument is flexible in terms of 
its ability to measure reflected spectra from any PC surface, regardless of whether the PC 
is incorporated into stagnant microplate wells, flow channels, or continuous PC 
microscope slides. 
 
1.2.4 Device operation 
Driving fluids to flow through the microchannels was accomplished by pre-filling 
one or more microplate wells with solution, and application of pneumatic pressure.  After 
the microplate wells were pre-filled with solution, a silicone cap attached to Teflon 
microtubing (Cole-Parmer) was inserted into the opening of the well and a pressure 
regulated lab pneumatic source (2.5 psi) was used to drive liquid through the channels. 
 
1.2.5 Reagents 
Phosphate buffered saline (PBS), glutaraldehyde, biotinylated heparin, and human 
lactoferrin were purchased from Sigma-Aldrich.  Starting Block blocking buffer was 
purchased from Pierce Biotechnology.  Streptavidin was purchased from Prozyme.  




1.3.1 Heparin-lactoferrin assay 
Optical biosensors employing surface binding detection are most often used to 
quantify the affinity of an analyte for its ligand.  To provide a realistic demonstration of 
the assay chip for determining binding affinity between biomolecules, the sensor 
response to a concentration series of lactoferrin, where the sensor surface is immobilized 
with heparin, was investigated.  Protein interactions with heparin mediate many 
biologically important process [27].  Therefore, the characterization of the affinity and 
kinetics of these interactions has been of considerable interest [28].  Lactoferrin is a 
soluble iron-binding glycoprotein with antimicrobial and anti-inflammatory activity, and 
heparin is a sulfated polysaccharide that comprises much of the extracellular matrix of 
many cell types and is used extensively as an anticoagulant drug [27, 29].  For this 
experiment, the heprin/lactoferrin pair was chosen because it exhibits classical 
association and dissociation kinetics behavior.  Heparin used for the experiment was 
biotinylated so that it could bind to a layer of streptavidin attached to the sensor surface 
through a thin polymer coating and bifunctional linker, using an immobilization 
procedure that has been described previously [30].  
Initially, the sensor-integrated microfluidic channels were washed by flowing 
deionized (DI) water solution from the common well into the channels.  Next, the 
microchannels were filled with a 4% amine polymer solution in DI water and incubated 
at 25 °C for 24 hr.  After washing the channels with DI water, glutaraldehyde (25% in DI 
water) was flowed through and incubated at 25 °C for 2.5 hr.  After washing the channels 
with DI water, streptavidin (0.5 mg/mL in DI water) was filled and incubated at 4 °C for 
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24 hr.  The channels were then washed with DI water, followed by PBS conditioning.  
The capture molecule (biotinylated heparin) was then immobilized onto the sensor 
surfaces of all the channels by flowing the solution (0.1 mg/mL in PBS) from the 
common well into the channels and incubating at 4 °C for 12 hr, followed by a PBS wash 
to remove unbound excess biotin-heparin molecules.  The 2-dimensional spatial PWV 
shift image after heparin immobilization/wash obtained by operating the detection 
instrument in the spatial imaging mode is shown in Figure 1.4.  The PWV shift image 
was acquired on a pixel-by-pixel basis by subtraction of the PWV image before heparin 
immobilization from the PWV image after wash.  PWV shifts are represented by the 
scale bar from -1.50 to 1.50 nm with red regions representing areas of greatest positive 
shift.  After the heparin immobilization and wash, the unbound regions of the channels 
were blocked with Starting Block blocking buffer for 1 hr.  The channels were then 
washed with PBS solution and a concentration series of lactoferrin (200, 100, 50, 25 
µg/mL in PBS) and a negative control (PBS) was added to each of the analyte wells.  
After the wells were pre-loaded with the analyte and buffer solutions, the data acquisition 
from the detection instrument was initiated in the kinetic mode, and the solutions were 
pumped from each of the analyte wells to the detection area and to the common well.  At 
the end of the association phase, a wash step was performed by rinsing and filling the 
analyte wells with PBS while the solutions were continuously pumped.  After the wash 
step, the reference channel was filled and pumped with a 2 mg/mL concentration of 




Figure 1.4  Spatial PWV shift image obtained after heparin immobilization and wash.  PWV shifts 
are represented by the color coded scale bar from -1.50 to 1.50 nm with red regions representing 
areas of greater positive shift. 
 
1.4 Results 
The kinetic PWV response of lactoferrin binding to the heparin-immobilized 
sensor is shown in Figure 1.5.  The width of each fluid channel was 300 µm, 
corresponding to 13 data pixels across (pixel resolution: 22.3 µm), but the PWV response 
for each channel was calculated by averaging only 7 pixels (156 µm) in the center region 
across the channels where the fluid flow rate was constant.  We assume that the flow rate 
is constant in the center region of the channel because the channel width is significantly 
larger than its height.  The average standard deviation for the 7 pixel measurement 
observed was 0.0057 nm.  The average PWV shift data in Figure 1.5 were obtained by 
subtracting the average PWV of the reference channel filled with PBS buffer from the 
average PWV for each active channel with lactoferrin to remove effects of signal drift 
that are not due to heparin-lactoferrin interaction.  The duration of the 
association/dissociation measurement was 5 min, with PWV measurements taken at 1 sec 
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intervals.  A negative pressure of -2.5 psi was applied to the common well 65 sec after 
the initiation of the PWV measurement to introduce the analyte solution over the 
detection area, and this resulted in a fluid flow rate of 32.7 µL/min for each channel. 
 
Figure 1.5  Kinetic PWV response of heparin immobilized microfluidic PC sensors for lactoferrin 
exposure of different concentrations. 
 
Based on the binding interaction between an analyte and a ligand described by the 
standard equilibrium reaction rate equation, change in the sensor response as a function 
of time is given by the ordinary dynamic surface binding equation 
 
   RkRRAk
dt
dR
da  max  
 
where [A] is the analyte concentration, Rmax is the maximum capacity of the immobilized 
ligand, R is the biosensor signal which is proportional to the amount of bound molecules 
[AL], ka is the association rate constant, and kd is the dissociation rate constant.  Rmax – R 
is proportional to the amount of ligand available for binding that is not already bound 
(1.1) 
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with analyte molecules.  As shown in previous work involving biosensor output response 
to an analyte introduced within a flow stream, the association phase response is obtained 













Therefore, the plot of initial sensor response rate against analyte concentration 
results in a linear relationship whose slope is ka∙Rmax with an intercept of zero.  Using this 
analysis, the association rate constant between heparin and lactoferrin can be determined 
from the kinetic biosensor response data.  Likewise, the dissociation rate constant can be 
determined by solving Equation 1.1 during the dissociation phase where it is assumed 
that [A] = 0, resulting in the expression 
 
      RtkRRR dexp0  
 
where 0R  is the sensor response at the start of the dissociation, and R is the final steady 
state response.  The dissociation constant, or DK  value for the heparin-lactoferrin 






K  . 
The initial sensor response rate was determined from the kinetic binding data 
obtained in Figure 1.5 where the rate was calculated over the linear regions of the binding 
curves.  The initial binding data used to calculate the association rate constant ranges 




the initial slope was calculated using more data points for greater precision since sensor 
response data at lower analyte concentrations are linear for a longer period of time.  The 
plot of initial sensor response rate as a function of lactoferrin concentration is shown in 
Figure 1.6.  A linear fit was applied to the data using a least squares method with the y-
intercept set to zero, yielding a slope (ka∙Rmax) of 
41093.3  nm (µg/mL)-1 sec-1 with an 
R
2
 value of 0.998.  Using the maximum binding capability (Rmax) determined by 
introducing 2 mg/mL concentration of lactoferrin, the association rate constant for 
heparin-lactoferrin binding was calculated as 41028.2  (µg/mL) -1 sec-1.  Based on the 
dissociation curve fitting, the dissociation rate constant was determined to be 
41049.60143.0  sec-1.  As a result, the DK  value for the heparin-lactoferrin 
interaction was determined to be 63.1 ± 2.85 µg/mL. 
 
 
Figure 1.6  Plot of initial binding rate measured between heparin and different concentrations of 
lactoferrin. 
 
In order to verify the DK  value determined using the PC microfluidic assay chip, 
another heparin-lactoferrin assay was performed on a commercially available standard 
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96-well microplate PC biosensor.  The biosensor microplate detection of heparin-
lactoferrin binding was performed simultaneously with the microfluidic assay using the 
identical reagents and immobilized ligand surface preparation method.  The only 
significant difference between the biosensor microplate assay and the flow channel assay 
is that the microplate assay occurs without the use of active flow, resulting in biosensor 
response rate that is limited by the rate of diffusion of lactoferrin to the bottom surface of 
the microplate well.  Figure 1.7 shows the kinetic PWV response of heparin immobilized 
PC sensors for lactoferrin exposure of different concentrations in a standard well plate 
format. In order to perform an end-point concentration series assay without fluid flow, 
the sensor measurement had to be taken for at least 55 min until a steady state 
equilibrium response is achieved.  Figure 1.8 depicts the end-point PWV shift from the 
microplate-based sensor, 55 min after the lactoferrin introduction, as a function of 
lactoferrin concentration ranging from 3.13 to 1000 µg/mL.  The data in Figure 1.8 was 
fit with a dose response sigmoidal curve with an R
2
 value of 0.984 and the DK  value was 
determined to be 60.63 µg/mL. 
 
Figure 1.7  Kinetic PWV response of heparin immobilized PC sensors for lactoferrin exposure of 




Figure 1.8  Dose response curve for heparin and lactoferrin measured on a conventional well plate 
based photonic crystal sensor.  Data represented as mean ± SD (error too small to be shown), N = 3. 
 
Using the PC integrated microfluidic assay chip, association/dissociation rate 
constants, and therefore the equilibrium constant ( DK ) for heparin-lactoferrin interaction, 
were determined.  To demonstrate the validity of the reaction equilibrium constant 
determined using the microfluidic based PC sensor chip, an alternate method to 
determine the DK  value of the reaction was used on a diffusion-limited PC biosensor 
microplate.  As shown in the experiment, the DK  value determined using the 
microfluidic based PC sensor chip comes within 4.07% of the DK  range determined 
using the conventional microplate PC sensor. 
The DK  value obtained using the PC microfluidic assay chip can also be 
compared to the heparin-lactoferrin interaction data previously measured using surface 
plasmon resonance (SPR) biosensors [28].  In that work, the analyte injection flow rate 
was 30 µL/min and the assay duration was 7 min.  Based on the sigmoidal curve fitting of 
dose response measurement reported in the literature, the DK  value determined by SPR 
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ranged from 10.50 to 30.94 µg/mL, where KD variation was attributed to differences in 
the heparin biotinylation method such as, biotinylation via uronic acids, intrachain bare 
amines, or the reducing terminus, which in turn affects binding affinity for the analyte.  
Although a different KD value than that reported in [28] was obtained from the 
experiment in this chapter, the value is similar considering the fact that a different surface 
chemistry method is used. 
 
1.5 Dicussion 
The 384-well fluid channel microplate reported here enables low volume kinetic 
analysis of protein-protein interactions through 5 analyte flow channels with a single 
control point and offers higher assay density format.  This device requires significantly 
shorter analyte travel distance (5 mm) from the inlet region to the PC detection region, 
compared to the 96-well microplate based microfluidic sensor format reported previously 
(64 mm), in which kinetic analysis could not be performed effectively.  The shorter 
analyte travel distance becomes important for accurate kinetic analysis of low analyte 
concentrations because short analyte travel distance enables very low flow latency and 
reduces the effect of analyte molecule depletion before reaching the detection region.  For 
the device in this chapter, there was no flow latency between channels whereas with the 
previous 96-well plate microfluidic device, it was difficult to create low levels of flow 
latency (flow latency up to 7 sec was observed) [22].   Ideally, the fluid flow rate among 
all channels should be kept identical for accurate kinetic analysis.  Another consequence 
of long flow path length is the difference in the flow rate observed during the kinetic 
measurement.  The analyte flow rate for the previous literature was 0.442 µL/min, which 
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is significantly lower than 32.7 µL/min for this work.  A flow rate of 0.442 µL/min is too 
low for accurate kinetic analysis as the reaction rate becomes limited primarily by mass 
transport, rather than kinetic binding rate.  Comparing the active surface area attached 
with binding sites, the previous 96-well plate based device has 13× more surface area 
available for binding than the device presented in this chapter.  For lower analyte 
concentration assays, the level of analyte depletion due to the difference in binding site 
surface area becomes significant.  FEM software (COMSOL) was used to verify the 
difference in the kinetic binding rate between the 96 and the 384-well plate based 
microfluidic channels.  A difference in the kinetic binding rate was observed in the 
simulation even with the analyte flow rate set to be identical for both cases.  With the 96-
well plate microfluidic device, reduction in the end-point binding assay time was 
achieved, but kinetic analysis could not be effectively achieved due to its long channel 
length.  The biosensor microfluidic microplate presented here is capable not only of 
significantly reducing the assay time, but also of accurately characterizing biochemical 
kinetic binding constants. 
Examination of the methods used to obtain DK  for the same protein-protein 
interaction using the identical biosensors packaged in two different formats (microfluidic-
based detection versus stagnant microplate well detection) yields interesting comparisons 
in terms of reagent usage and assay time.  First, the mass of biotinylated heparin used to 
generate an immobilized ligand layer in the 96-well microplate format was compared 
against the mass required to prepare the microfluidic chip.  For the standard 96-well 
biosensor microplate (SRU Biosystems)-based assay for determination of DK , 5 analyte 
(lactoferrin) concentrations are required to generate a dose-response curve, and triplicate 
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wells are used for each concentration.  Using 100 L volumes of 100 g/mL biotinylated 
heprarin solution, therefore, results in the use of 150 g of biotinylated heparin reagent.  
Performing heparin immobilization within 3 microfluidic channels, using the same 
concentration solution, required only 15 g of the ligand.  One channel per concentration 
was used during the experiment in this work, but 3 channels per concentration were used 
to calculate reagent mass usage for comparison.  This appears to be a substantial 
advantage for the microfluidic approach.  However, biosensor microplate wells in the 
384-well and 1535-well format are also available (although not used in the experiment 
reported here).  In the 384-well microplate format, for example, only 20 L of heparin 
solution would be needed to prepare each biosensor well, resulting in a heparin mass 
usage of 30 g, which is similar to the microfluidic mass usage.  The mass of lactoferrin 
analyte required for determining DK  by the two methods may also be compared as well.  
For the standard 96-well microplate biosensor (SRU Biosystems), 4 different 
concentrations of lactoferrin were used (25 – 200 g/mL) with triplicate wells at 100 L 
volume for each well for each concentration, resulting in a total lactoferrin mass of 113 
g.  In the microfluidic experiment reported here, the same concentrations of lactoferrin 
were used.  With the flow rate of 32.7 µL/min measured per channel, assay association 
time of 2.2 min, and assuming triplicate flow channels for the experiment, 81 g of 
lactoferrin would be used.  Therefore, the amount of analyte protein used for the 
microfluidic-based methods would be slightly less.  For the SPR based experiment 
reported in [28], the amount of lactoferrin analyte consumption would be 74 µg assuming 
a 30 µL/min flow rate and an assay association time of 2.2 min.  A summary of flow rate, 
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analyte mass required, and measured KD value for different assay platforms is shown in 
Table 1.1.  
 




 With the standard microplate format based biosensors, the reaction kinetics within 
the plate wells are dominated by the rate of diffusion of analytes to the sensor surface, 
unless external mixing is provided.  Therefore, kinetic biosensor data do not provide 
reaction rate data on analyte-ligand interactions with the same utility as biosensors 
incorporated within microfluidic channels, where the analyte diffusion distance is 
significantly reduced.  As a consequence, different analysis methods to determine the DK  
value are used for the microplate-based format versus the microfluidic based format.  The 
DK  value analysis for the standard microplate format assay is based on fitting a dose-
response curve (end-point analyte concentration series assay) which requires sensor 
measurements to be taken until equilibrium response is reached.  For the microfluidic 
flow based assay, however, the DK  value determination is based on fitting kinetic 
association and dissociation data.  Therefore, both the association and dissociation rate 
constants ( ak  and dk ) as well as the equilibrium constant ( DK ) can be determined with 
microfluidic based PC sensors, whereas only the DK  value can be determined with the 
conventional microplate-based format.  
 22 
Another consequence of mass transport limitation in the standard well plate 
format is the longer detection time required for the bioassay.  In order to perform an end-
point concentration series assay without fluid flow, the sensor measurement has to be 
taken until a steady state equilibrium response is achieved.  Therefore the KD values of 
the microplate and the microfluidics-based experiments matched, but in the case of 
microplate based assays, it takes more time for the equilibrium of the sensor response to 
be reached compared to the microfluidic assay.  For the heparin-lactoferrin assay 
performed on a microplate sensor in this work, the assay time required for the sensor 
response to reach equilibrium for DK  value determination was 55 min, compared to 5 
min for the microfluidic based PC biosensor (Figure 1.5).  While the microfluidic chip 
based assay was run for 5 min, the actual time required for reaction rate constant 
determination is even less for the initial rate analysis since only a few data points are 
required after the analyte introduction.  Initial rate analysis was used to determine the 
reaction rate constant because of its simplicity compared to exponentially fitting full 
association profiles and the need for fewer data points and thus less data collection time.  
Analyzing the initial portion of the association/dissociation profiles corresponds to 
binding of only a small fraction of analytes and therefore allows analysis before steric 
crowding, analyte depletion or mass transport effects become dominant [31].  Therefore, 





A PC biosensor integrated microfluidic chip for measuring biomolecular 
interaction information was developed.  The device’s capability to determine kinetic 
binding information was verified through a heparin-lactoferrin concentration series assay 
using a detection instrument capable of measuring sensor response at high spatial 
resolution.  The microfluidic device reported in this chapter incorporates the traditional 
advantages of flow-channel based biosensor assays, such as low reagent consumption and 
rapid response time.  The plastic-based replica molding fabrication approach would 
enable the sensor structure to be inexpensively manufactured and features an external 
fluid interface that matches a 384-well microplate footprint, and is thus readily 
compatible with the liquid handling infrastructure that is most commonly available within 





CHAPTER 2: COMPARISON OF LABEL-FREE BIOSENSING IN 
MICROPLATE, MICROFLUIDIC, AND SPOT-BASED AFFINITY CAPTURE 
ASSAYS 
2.1 Introduction 
Label-free biosensors operate through transduction of some intrinsic physical 
quantity associated with biological analytes that can include small molecules, peptides, 
proteins, DNA, viral particles, bacteria, or cells [15, 32-36].  Accumulation of analyte 
upon the biosensor surface results in changes in the mass density, dielectric permittivity, 
or some other physical quantity that can be transduced to a measurable output signal [19].  
The resulting signal is a product of the complex interaction involving the chemical 
equilibrium between an immobilized capture ligand and the detected analyte, in which 
both attachment and detachment occur simultaneously.  The sensor output signal is also 
affected by the mass transfer, which may limit the rate of delivery of analyte molecules to 
the surface, and the loss of available analyte molecules due to scavenging by surfaces 
other than those incorporating a sensor.  Along with the sensor signal output level, the 
readout background noise, which determines how large a signal must become in order to 
be considered statistically detectable, is an important quantity.  In a biological or 
chemical sensor system, the sensor’s scale factor (that transduces the adsorbed analyte 
quantity to the output signal), the noise characteristics of the detection method, the 
surface chemical equilibrium, and the mass transfer of analyte to the surface interact 
together.  This interaction determines the assay detection limits, the amount of time 
required to accumulate a measureable signal, and whether a detectable signal should be 
achievable at all for a given system.   
 25 
 Label-free biosensors have often been designed to function in the context of a 
flow cell – a microfluidic channel that brings the analyte solution to the sensor [21, 37-
41].  Typically in these systems, the sensor is “activated” with an immobilized capture 
ligand by flowing a solution through the channel, resulting in accumulation of capture 
molecules upstream of the sensor region.  By providing sufficient concentration of 
analyte and flow rate, mass transfer limitations on the detection of analyte can be 
overcome, but for low analyte concentrations, capture molecules in regions other than the 
detection region will “steal” available molecules before they can be detected.   
 Several technologies have demonstrated the capability for increasing the 
throughput of label-free biosensor measurements by incorporating sensors into the wells 
of standard format microplates [12, 42].  While increasing the number of assays that can 
be performed in parallel, these systems have finite assay volumes, a finite number of 
detectable molecules, and generally no flow.  In addition, new technologies have 
demonstrated the capability for high spectral resolution molecular detection employing 
ultra high Q-factor resonators [43, 44] and for high resolution imaging detection, in some 
cases with the ability to also provide kinetic information on binding [12, 45-48] or 
implementation of arrays of individual sensors on a chip [49-52].  For these technologies, 
capture ligands are placed in an array of discrete regions of the active biosensor surface 
or upon discrete sensors in the form of nL – pL volume droplets using technologies 
capable of performing accurate droplet deposition using physical contact with metal pins, 
piezoelectric dispensers, and acoustic droplet ejection [53].  In comparison to methods 
that involve coating the entire inner surfaces of a microplate well or flow channel with 
capture ligand, spot-based assays can potentially reduce loss of analyte molecules to 
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unwanted surfaces, thus serving to concentrate detected molecules upon the biosensor 
active area.  Therefore, spot-based methods are expected to provide benefits in achievable 
detection limits. 
 Detection of trace quantities of biological analytes by a label-free detection 
system involves a large number of experimental variables and system design parameters.  
In the design of an assay, it would be valuable to be able to make accurate analytical or 
numerical predictions of the magnitude of a measured signal, the evolution of a signal 
over time, and the conditions under which signals will exceed system noise limits.  The 
goal of the work in this chapter, therefore, is to develop a comprehensive physical model 
for a general label-free biosensor system that includes the liquid-handling system as an 
integral part of the model, taking into account the effects of surfaces with which the 
analyte solution comes into contact.  Although the model shown in this chapter is 
applicable to any label-free biosensor, a single label-free detection platform, the photonic 
crystal (PC) biosensor, was used as a means for comparing the model to experimentally 
obtained measurements.  The PC biosensor is especially advantageous for this purpose 
because it has been demonstrated in microplate format [12], microfluidic format [22, 25, 
54], and spot-based assays with a high resolution imaging system [55].  Therefore, the PC 
biosensors with equivalent performance specifications could be implemented in each of 
these assay formats for direct comparison.  As an example assay, the detection of the 
protein tumor necrosis factor-alpha (TNF-α) using its capture antibody (anti-TNF-α) is 
simulated and demonstrated.  Finite element analysis was performed using COMSOL 
Multiphysics software, which models phenomena defined in different domains in a fully 
coupled manner. 
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2.2 Materials and Methods 
2.2.1 Microfluidic sensor fabrication 
The fabrication method used for the microfluidic-based sensors is the same as 
described in section 1.2.2, except that the anti-TNF-α immobilization surface chemistry 
(described in section 2.2.6) was performed on the open microfluidic channels before 
sealing with a top PET layer and packaging. 
 
2.2.2 Optical fiber probe instrument 
For the standard microplate based bioassay with the entire bottom surface 
immobilized with capture antibody, a BIND Reader instrument (SRU Biosystems) was 
used to illuminate the sensor and to detect the reflected signal [12].  To excite the 
reflected resonance, a broadband near-infrared light-emitting diode illuminates a ~2 mm 
diameter region of the sensor surface through a 400 μm diameter optical fiber and a 
collimating lens at normal incidence through the bottom of the microplate.  A detection 
fiber for gathering reflected light is bundled with the illumination fiber for analysis with a 
spectrometer.  A series of 8 illumination/detection heads are arranged in a linear fashion, 
so that reflection spectra are gathered from 8 wells in a microplate column at once.  The 
microplate sits on a motion stage so that each column can be addressed in sequence.  The 
instrument is capable of measuring 96 wells in 15 sec, though more rapid kinetic 




2.2.3 Imaging instrument 
For microfluidic-based assays and spot-based microplate assays where PWV 
shifts of small local features on the sensor surface need to be measured, the optical fiber 
probe system described above cannot be used since its illumination spot size is 2 mm in 
diameter.  Instead, an instrument that is capable of measuring PWV shifts with high 
spatial resolution is required.  The high resolution imaging detection instrument was 
described previously in section 1.2.3.  
 
2.2.4 Assay configurations 
The four assay configurations are illustrated in Figure 2.1, where the schematics 
in the figure represent a view of the devices from above looking down into the wells.  
The areas highlighted in red indicate regions where capture antibodies (ligands) are 
immobilized.  The microfluidic assay with capture antibody immobilized on the entire 
surface of the microchannel walls, which will be referred to as “Channel-Whole,” is 
shown in Figure 2.1a and the microfluidic assay with capture antibodies locally spotted in 
a 500 µm wide strip placed on the detection region, which will be referred to as 
“Channel-Spot,” is shown in Figure 2.1b.  The arrow in Figure 2.1a indicates the 
direction of fluid flow during the analyte binding step.  In Figure 2.1a and b, six 384 
wells are displayed.  The standard 384-well microplate assay configuration with the 
entire bottom surface of the well immobilized with capture antibody, referred to as 
“Well-Whole,” is shown in Figure 2.1c.  The assay configuration with 4 spots of capture 
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antibody (100 µm diameter) placed within a single well of a 384-well microplate sensor 
is shown in Figure 2.1d, which will be referred to as “Well-Spot.”  One 384 well is 
displayed in Figure 2.1c and d. 
 
Figure 2.1  Schematic diagram of the assay configurations.  The areas highlighted in red indicate 
regions where capture antibodies are immobilized.  (a) Microfluidic sensor with entire bottom 
surface immobilized with capture antibody (Channel-Whole).  The arrow indicates the direction of 
fluid flow during analyte binding step.  (b) Microfluidic sensor with localized ligand immobilization 
(Channel-Spot).  (c) Standard 384-microplate device with entire bottom surface immobilized with 
ligand (Well-Whole).  (d) Standard 384-well micoplate with four immobilized ligand spots (Well-
Spot).  Six 384 wells are displayed in a, b and one 384 well is displayed in c, d. 
 
2.2.5 Assay reagents 
Human TNF-α and biotinylated anti-human TNF-α capture antibody (MAb11) 
were purchased from BioLegend.  Phosphate buffered saline (PBS), Tween 20, and 
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Glutaraldehyde were purchased from Sigma-Aldrich.  BioFX milk blocker solution was 
purchased from BioFX Laboratories.  Streptavidin was purchased from Prozyme.  Amine 
polymer was obtained from SRU Biosystems and 3-
glycidoxypropyldimethylethoxysilane was purchased from Gelest. 
 
2.2.6 Surface chemistry 
 For the microfluidic based assays (Channel-Whole and Channel-Spot), the anti-
TNF-α used for the surface chemistry was biotinylated so that it could bind to a layer of 
streptavidin attached to the sensor surface through a thin amine polymer coating and a 
bifunctional linker using an immobilization procedure described previously [30].  
Initially, the sensor-integrated microfluidic channels were washed by flowing deionized 
(DI) water solution from the common well into the channels.  Next, the microchannels 
were filled with a 4% amine polymer solution in DI water and incubated at 25 °C for 24 
hr.  After washing the channels with DI water, glutaraldehyde (25% in DI water) was 
flowed through and incubated at 25 °C for 2.5 hr.  After washing the channels with DI 
water again, streptavidin (0.5 mg/mL in DI water) was filled and incubated at 4 °C for 24 
hr.  The channels were then washed with DI water, followed by PBS conditioning.  For 
the Channel-Whole device, the anti-TNF-α solution (0.25 mg/mL in PBS) was placed 
onto the entire open channel.  For the Channel-Spot device, the anti-TNF-α solution was 
spotted onto the open channels by a piezo array spotter (Perkin Elmer) in a 4 × 30 array 
with spot-spot distance of 150 µm and each spot utilizing 300±30 pL of volume.  The 
spot array was then repeated twice in the same location to ensure uniform antibody 
density across the strip with enough spot volume for sufficient immobilization.  The 
 31 
spotting was done inside a closed chamber with humidity control and substrate 
temperature set to 12 °C.  The anti-TNF-α solution on both the Channel-Whole and 
Channel-Spot devices was then incubated at 4 °C for 18 hr, followed by a PBS wash to 
remove unbound excess anti-TNF-α.  The 2-dimensional spatial PWV image of the 
Channel-Spot device shown in Figure 2.2 was obtained by operating the detection 
instrument in the spatial imaging mode.  The PWVs are represented by the color scale 
ranging from 860 to 865 nm, where the red region represents area of greater PWV.  It can 
be observed from the image that the localization of the anti-TNF-α immobilization is 
achieved.  After the anti-TNF-α immobilization and wash, the open microfluidic channels 
were dried and sealed by a separate PET sheet.  Then they were packaged by attaching to 
a bottomless 384-well microplate using an adhesive as described in the device fabrication 
section.   
 
Figure 2.2  Two-dimensional spatial PWV image of the microfluidic PC sensor device after spot-
based immobilization of anti-TNF-α.  The PWV are represented by the color scale ranging from 860 
to 865 nm, where red regions represent areas of greater PWV.  It can be observed from the image 
that the localization of the anti-TNF-α immobilization is achieved. 
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 The anti-TNF-α immobilization on the Well-Whole device was performed using 
the same reagents and capture antibody surface preparation method as for the Channel-
Whole and Channel-Spot devices.  The entire sensor surfaces on the bottom of the 
microplate wells were immobilized with anti-TNF-α by pipetting 50 µL of the solution 
(0.25 mg/mL in PBS) into each well, incubating for 18 hr at 4 °C, followed by PBS wash 
and a PWV measurement using the optical fiber probe instrument (SRU Biosystems). 
The Well-Spot configuration experiment was performed using a standard PC 
biosensor microscope slide (1 × 3 inch) and a 384-well size gasket containing a column 
of 16 wells from SRU Biosystems.  The PC biosensor slide was initially surface treated 
by incubation in an enclosed chamber with 5% 3-glycidoxypropyldimethylethoxysilane 
in dry toluene at 100 °C overnight.  Next, the slide was rinsed with toluene and DI water, 
and dried with a nitrogen gun.  The PC biosensor surface was then spotted with an array 
of 16 vertical groups of 4 distinct spots of anti-TNF-α in PBS with 0.01% Tween (assay 
buffer) at 0.5 mg/mL, and allowed to bind for 18 hr at 4 °C.  Epoxysilane-based surface 
chemistry was used for the Well-Spot device because a hydrophobic sensor surface was 
required to prevent the antibody spots from spreading on the sensor surface, particularly 
along the PC grating lines.  The piezoarray spotting conditions were identical to those 
used for the Channel-Spot device.  After the incubation, the gasket was applied to the 
sensor surface, where each group of the 4 spots sits in one well.  The spots were washed 
with a large volume of PBS with 2% Tween (wash buffer) and stabilized in 15 L of PBS 
with 0.01% Tween, followed by a spatial PWV shift measurement with the imaging 
instrument operated in the imaging mode. 
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2.2.7 Binding constant determination 
The association and dissociation constants of the TNF-α and anti-TNF-α were 
determined using the PC integrated microfluidic sensor device through initial rate 
analysis and dissociation curve fitting, which was previously demonstrated [31, 56].  
TNF-α concentrations of 0.2, 1, 5, 10 µg/mL in PBS, and a blank PBS solution as the 
reference, were introduced into the PC integrated microfluidic chip immobilized with 
anti-TNF-α on the sensor surface.  The wash buffer flow was introduced into the 
channels 5 min after the introduction of analyte solution in order to observe the 
dissociation kinetics.  Driving fluids to flow through the microchannels during the 
association/dissociation phase was accomplished by prefilling one or more analyte wells 
with solution, followed by application of pneumatic pressure. After the analyte wells 
were prefilled with solution, a silicone cap attached to Teflon microtubing (Cole–Parmer) 
was inserted into the opening of the common well and a pressure-regulated lab pneumatic 
source was used to drive liquid through the channels.  Due to the short analyte travel 
distance, no flow latency between the five microchannels was observed when the analyte 
solutions were driven through.  The anti-TNF-α immobilization protocol for the binding 
constant determination experiment is identical to the protocol for the microfluidic-based 
TNF-α assay which was described in the previous section.  The association constant of 
the TNF-α and anti-TNF-α pair was determined using the initial rate of the sensor 
response.  The dissociation constant was then determined by fitting the dissociation 
kinetic curves obtained from each of the four analyte channels (one analyte channel was 
filled with buffer solution) to the solution of the reaction rate equation during the 
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dissociation phase.  Using this method, the association constant measured for the TNF-α 
and anti-TNF-α pair was 0.00727 (µg/mL)-1 sec-1 and the average dissociation constant 
measured was 0.0176 ± 0.00657 sec
-1
, where ± value represents one standard deviation.  
The kinetic rate constants measured in this experiment yield a binding affinity of Kd = 
0.121 ± 0.0452 μM which is comparable to previously measured values of 0.231 – 0.542 
μM for human TNF-α and anti-human TNF-α monoclonal antibodies obtained with a 
quartz crystal microbalance (QCM) biosensor [57].  The slight difference in the measured 
binding affinity with the QCM system is likely due to the use of different types of MAb 
(Z8 and Z12) and different surface chemistry methods (self-assembled thiol on Au) for 
immobilizing capture antibodies to the quartz crystal. 
 
2.2.8 Assay procedure 
 For the microfluidic devices (Channel-Whole/Channel-Spot), after the surface 
chemistry and sealing the open channels, the regions of the channel surface unbound by 
anti-TNF-α were blocked with 1× concentration BioFX blocking buffer by incubating for 
2 hr, followed by a PBS wash.  After the surface block/wash, TNF-α concentration series 
of 40, 200, 1000, 2000 ng/mL
 
(in PBS), and a blank PBS solution as a negative control, 
were pre-loaded in each of the analyte wells.  Next, data acquisition was initiated with the 
imaging instrument in the kinetic mode, and the solutions were pumped from each of the 
analyte wells through the detection area and then to the common well by applying 5 inHg 
of negative pressure at the common well.  During the kinetic measurement, the data 
acquisition line of the imaging instrument was aligned to the center of the localized anti-
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TNF-α region of the Channel-Spot device and the same image location was used for the 
Channel-Whole device.   
 For the Well-Whole device, regions unbound by anti-TNF-α were also blocked 
with 1× concentration BioFX blocking buffer by incubating in the wells for 2 hr, 
followed by a PBS wash.  A range of TNF-α sample concentrations (1, 10, 100, 1000, 
10000 ng/mL in PBS), and PBS buffer as a reference, were pipetted into separate wells 
(50 µL).  Kinetic measurement of TNF-α binding for the Well-Whole device was 
performed using the optical fiber probe instrument.   
 As with the previous assay configurations, sensor regions unbound by capture 
antibodies of the Well-Spot device were blocked by placing 90 L of 1× concentration 
BioFX blocker solution in the wells and incubating for 2 hr.  After blocker incubation, 
the wells were washed with a large volume of the wash buffer and stabilized in 15 L of 
assay buffer.  After stabilization, the sensor surface was scanned with the imaging 
detection instrument in the spatial imaging mode to obtain a PWV image after blocker 
immobilization.  The TNF-α samples were prepared in a concentration series of 1, 5, 10, 
25, 50, 100, 500, 1000, and 5000 ng/mL in pre-surface blocked centrifuge tubes.  The 
prepared solutions were pipetted directly into each well (50 L), including two wells with 
only an assay buffer as reference wells.  The anti-TNF-α spots were allowed to incubate 
with the TNF-α concentration series overnight at 4 °C.  The wells were all washed with 
large volume of wash buffer, stabilized with 15 L of assay buffer, and a final scan was 
made with the imaging instrument to obtain PWV image of TNF-α binding. 
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2.2.9 Computer simulations 
 Finite element method (FEM) software (COMSOL) was used to model the kinetic 
sensor response as analyte molecules in the bulk solution are transported and diffused to 
bind with the capture molecules available on the sensor surface.  The governing 
differential equation used for the analyte concentration in the bulk solution was the 










where c , D , and u

 are the bulk analyte concentration, bulk diffusion constant and fluid 
flow velocity vector, respectively.  For the flow velocity field u

, the parabolic fluid flow 
velocity profile derived from the incompressible fluid Navier-Stokes equation with no-
slip boundary condition was used.  At the sensor surface where the ligand-analyte binding 
reaction occurs, the governing differential equation for the surface bound analyte 











where sc  is the surface concentration of the analyte bound to the sensor surface, ak  is the 
association rate constant, dk  is the dissociation rate constant, and 0  is the surface 




represented by coupling of the rate of reaction at the surface with the flux of the reacting 
species and the concentration of the adsorbed species and bulk species as:  
 




At the inlet of the channel where analyte solution is introduced, the boundary condition 
used was 0cc   and the boundary conditions for the outlet and the channel wall were 
  ucnuccDn

  and   0 uccDn

, respectively.  Figure 2.3 shows the 
mesh used for the FEM simulation of kinetic analyte-ligand binding.  A finer mesh was 
used in the bottom surface region where the highest analyte concentration gradient occurs 
(analyte molecules in the surface region bind with the surface immobilized ligands).  The 
probe locations for the microfluidics-based sensor were 250 µm (analyte travel distance 
to the midpoint of the 500 µm wide capture antibody strip across the channels) from the 
inlet for the Channel-Spot device and 5 mm (analyte travel distance to the imaging 
instrument’s measurement location from the analyte inlet) for the Channel-Whole device.  





 and kd = 0.0176 ± 0.00657 sec
-1 
(determined from the binding constant 
measurement) were used.  For the surface density of the capture antibody, 22.5 ng/mm
2
 
was used based on the analysis of the spatial PWV scan image after the antibody 
immobilization, where surface mass density to PWV shift ratio of 9 ng/mm
2
 per 1 nm 
PWV shift was used.  For the flow velocity within the channel, a parabolic flow profile 
with maximum velocity of 45 mm/sec was used.  This velocity was determined from a 3-




Figure 2.3  FEM mesh used for the assay configurations investigated.  (a) Microfluidic based sensor 
(Channel-Whole/Channel-Spot).  (b) Microplate sensor with entire bottom surface immobilized with 




The kinetic binding results from the simulation were compared with the 
experimental measurements.  Figure 2.4 shows the resulting plots comparing the 
theoretical and experimental kinetic PWV shift of anti-TNF-α immobilized microfluidic 
assay chips with introduction of TNF-α analyte of concentrations ranging from 0.04 to 2 
µg/mL.  Figure 2.4a and Figure 2.4b display the kinetic PWV shift for the Channel-
Whole and Channel-Spot devices, respectively.  The simulation results of the kinetic 
PWV shift are plotted as thin lines with dash lines indicating upper and lower simulated 
sensor response levels from ±1 standard deviation associated with the measurement of the 
kinetic dissociation rate, kd, and the experimental results are plotted in larger circular 
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points.  The plots show that the experiments terminated earlier than the simulations due 
to the TNF-α reagent in the analyte wells running out.  The analyte wells were not refilled 
with extra TNF-α reagents because the total analyte quantities consumed from the 
channel-based experiments would be very large for the duration of the experiment to last 
over 20 min.  This demonstrates the motivation behind using the FEM model to predict 
the response of label-free biosensor without having to exhaust large quantities of 
expensive analytes.  The differences observed between the theoretical and experimental 
kinetic shifts could be attributed to the factors that were not included in the FEM model, 
which are the channel-to-channel variability from the fabrication process, non-
uniformities in the capture antibody immobilization density between the channels, and 
non-specific binding that may still occur in the regions of the channels with no capture 
molecules despite the blocking step.  The factors mentioned above would also cause both 
the disagreement between theory and experiment for different analyte concentrations and 
that between the Channel-Spot and Channel-Whole devices.   Nonetheless, close general 
agreement was observed between the computer modeled sensor response and the 
experimentally measured sensor output for both the magnitude of the wavelength shift 
and the rate of response without the use of any parameters in the computer model that 
were not experimentally determined. 
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Figure 2.4  Theoretical and experimental comparison of kinetic PWV shift of anti-TNF-α 
immobilized microfluidic assay chip with introduction of TNF-α analyte of concentrations ranging 
from 0.04 to 2 µg/mL.  (a) Channel-Whole.  (b) Channel-Spot. 
          
Figure 2.5 shows the theoretical and experimental comparison of kinetic PWV 
shift of the Well-Whole device, where TNF-α analyte with concentrations ranging from 
0.01 to 10 µg/mL was used.  Again, the simulation result of the kinetic PWV shift is 
plotted as thin lines with dash lines indicating upper and lower simulated sensor response 
levels from ±1 standard deviation associated with the measurement of the kinetic 
dissociation rate, kd, and the experimental result are plotted in larger circular points.  As 
with the results for the microfluidic-based devices, the simulation and experimental 
results exhibit similar trends, without the use of any artificial scaling parameters in the 
computer model.  For the Well-Whole device, the discrepancies in the kinetic binding 
 41 
curves can be attributed mainly to the fact that the analyte solution in the well was 
modeled in the simulation as being completely stagnant.  In the actual experiment, fluid 
motion was introduced during the initial analyte reagent introduction through a pipette 
leading to rapid analyte convection to the antibody immobilized surface, indicated by 
consistently higher initial analyte binding rate observed in the experiment.  Also in the 
experiment, some capture antibodies were immobilized on the walls of the well along 
with the bottom surface, resulting in less than the modeled amount of analyte being 
available for binding.  As with the microfluidic-based sensors, non-specific binding on 
the regions not immobilized with capture antibodies can affect the binding kinetics. 
 
Figure 2.5  (a) Theoretical and experimental comparison of kinetic PWV shift of a Well-Whole 
device for TNF-α concentrations ranging from 0.01 to 10 µg/mL.  (b) Kinetic PWV shift for TNF-α 
concentrations of 0.01 and 0.1 µg/mL. 
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For the Well-Spot device, TNF-α binding measurements were made using the 
high resolution imaging detection instrument operated in the spatial imaging mode.  
Therefore, the PWV shift data from the analyte binding was obtained as end-points, 
rather than as kinetic plots, due to the extensive time required to scan through PC slide at 
high spatial resolution.  The end-point PWV shifts of the capture antibody immobilized 
spots were calculated by  considering the PWV shift of pixels in the spot region (active 
ligand spot) as compared to the PWV shift of regions adjacent to the spots (reference 
region), before and after injection of TNF-α.  Thus, the end-point PWV shift produced by 
TNF-α binding to the anti-TNF-α spots was obtained by measuring the PWV shift on the 
active ligand spot before and after the analyte introduction, and subtracting the PWV shift 
on the reference region before and after the analyte introduction.  The analysis method 
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This calculation was applied to each of the four spots in each well and the average of the 
four spots was taken to obtain the final PWV end-point value for each TNF-
αconcentration.  The simulated PWV end-point values along with the resulting 
experimental PWV shift end-point values as a function of the TNF-α analyte 
concentration are plotted in Figure 2.6.  The blue bar represents the computer simulation 
prediction of the PWV shift endpoint and the red bar represents the endpoint PWV shift 
(2.4) 
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obtained experimentally.  The experimental PWV shift values and the simulated PWV 
shift values show general agreement, exhibiting the same trend.  For lower analyte 
concentrations, larger % coefficient of variation (CV) values associated with lower sensor 
response levels should be considered for the comparison between the FEM simulation 
and experiment.  The consistently higher PWV shift for the experimental value can be 
attributed to the slightly higher level of TNF-α antibody activity in the active region from 
the epoxysilane-based surface chemistry.  The standard deviation values associated with 
the experimental end-point PWV shift plot, represented by the error bars, are mainly from 
the piezo array ligand spot-to-spot variability existing with the four spots within the well 
for each TNF-α analyte concentration.  The error bars for the simulated end-point PWV 
shift plot represent upper and lower shift levels from ±1 standard deviation associated 
with the measurement of the kinetic dissociation rate, kd. 
 
Figure 2.6  Theoretical and experimental comparison of endpoint PWV shift of a Well-Spot format.  
The blue bar represents theoretical endpoint PWV shift obtained from FEM simulation and the red 




With the validation of the simulation results through comparison with 
experimental measurements, the simulation results can be utilized to obtain predictions of 
molecular binding interactions in various circumstances.  The ability to predict the 
magnitude of a sensor response signal, the kinetics of the sensor signal (evolution of the 
signal over time), and the conditions under which signals will exceed system noise limits 
is extremely valuable.  Such capabilities are especially valuable for assays that are 
difficult to perform experimentally or for assays that must run for long durations.  
Therefore with the simulation model, the outcome of the bioassay can be predicted at a 
significantly lower cost without consuming reagents that may be expensive or only 
available in small quantities.  The binding kinetics model was used to examine the 
equilibrium PWV shift, to compare the amount of time required to reach equilibrium, and 
to investigate the detection limit for the four different bioassay configurations.  The 
equilibrium PWV shift values obtained from the simulation of the four different assay 
platforms are shown in Figure 2.7.  From the plot, it can be observed that the equilibrium 
PWV shifts for the Channel-Whole and Channel-Spot devices yielded the highest PWV 
shifts with identical equilibrium PWV shift amount for both configurations.  The Well-
Spot sensor yielded a slightly lower PWV shift that is comparable to the microchannel-
based sensors, and the Well-Whole device produced the lowest level of PWV shift.  
Comparing the assay conditions for the four configurations, the analyte sample was 
continuously replenished for the Channel-Whole/Channel-Spot devices and the amount 
of analyte volume relative to the ligand spot area was significantly larger for the Well-
Spot device compared to the Well-Whole device.  Therefore, higher levels of PWV shifts 
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observed in the Channel-Whole, Channel-Spot, and the Well-Spot device are due to the 
assay condition in which more analyte molecules are available for binding compared to 
the case for the Well-Whole device.     
 
Figure 2.7  Simulation result of final equilibrium PWV shifts of anti-TNF-α immobilized sensors for 
exposure to TNF-α concentrations ranging from 1 to 5000 ng/mL. 
 
 In bioassays, the time to reach equilibrium is important because the assay time 
directly affects the reagent consumption for flow-channel methods.  Consideration of 
assay time is also important for reagents that lose activity when exposed to room 
temperature for extended periods of time.  The plot for the time required to reach within 
5% of the end-point equilibrium value with respect to the analyte concentration for 
different assay configurations is shown in Figure 2.8.  Comparing the time required to 
reach equilibrium for all devices, the Channel-Whole/Channel-Spot devices reached 
equilibrium significantly faster than the Well-Whole/Well-Spot devices.  This is 
consistent with the assay condition difference in which the Well-Whole/Well-Spot assays 
were run without an active flow, resulting in a biosensor response rate that is limited by 
the rate of diffusion of TNF-α molecules to the bottom surface of the microplate well.  
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Comparing between the microplate-based devices, the Well-Spot device reached 
equilibrium faster than the Well-Whole device.  Between the microfluidic-based assays, 
the time required to reach equilibrium for the Channel-Spot device was less than the 
Channel-Whole device. 
 
Figure 2.8  Simulation result of time required to reach 5% within the equilibrium PWV shift for all 
assay configurations. 
 
 It should be noted that the equilibrium PWV shift value does not necessarily 
reflect the biosensor’s ability to measure analyte at low concentrations (limit of detection).  
Both the standard deviation of the PWV signal of the sensor measurement, along with the 
equilibrium PWV shift information, have to be considered in order to obtain the limit of 
detection.  With the PWV measurement setup used here, the standard deviations of the 
PWV signal measured were σ = 0.00220 nm for the Channel-Whole/Channel-Spot 
devices (imaging instrument in kinetic mode), σ = 0.00601 nm for Well-Spot device 
(imaging instrument in spatial imaging mode), and σ = 0.00203 nm for the Well-Whole 
device (fiber-optic probe instrument).  The difference in the standard deviation of the 
PWV signal is due to different measurement setups and methods employed for each case 
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(different probe area and averaging methods).  Based on the dose response curve and the 
sensor readout noise threshold values (3σ), the limits of detection for each of the sensors 
are 16.7 ng/mL for the Channel-Whole and Channel-Spot formats, 48.4 ng/mL for the 
Well-Spot format, and 30.9 ng/mL for the Well-Whole format.   
 For this work, the Channel-Spot device offers the fastest detection time with low 
probe molecule usage.  It also provides the lowest detection limit compared to the Well-
Spot/Well-Whole devices and has the added capability of being able to measure kinetic 
rate constants of biomolecular interactions.  Compared to the Channel-Spot format, the 
Channel-Whole format offers similar advantages and the same detection limit, but longer 
detection time is required.  However, the Channel-Whole format provides the advantage 
of a simpler assay protocol than the Channel-Spot device since the added equipment for 
dispensing reagents at specific locations is not required.  On the other hand, for the Well-
Spot format, the imaging instrument operating in the spatial imaging mode, which had 
the highest sensor signal standard deviation, was used to measure the PWV shift.  
Therefore, despite its equilibrium level being comparable to the Channel-Whole/Channel-
Spot devices and higher than the Well-Whole device, the limit of detection for the Well-
Spot device is higher and time required to reach the detection threshold level is longer.  
However, an advantage of the Well-Spot format is that probe molecule usage is lowest, 
making it suitable for assays that involve very expensive antibody reagents that are 
available only in small quantities.  The assay format also has the potential to achieve a 
lower limit of detection with improvements in the sensor readout noise level.  Although 
the detection times are significantly slower compared to the Channel-Whole/Channel-
Spot devices, Well-Whole/Well-Spot devices offer advantages in terms of analyte reagent 
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consumption since the reagent usage in the microplate devices is significantly lower as 
continuous flow of reagents is not required.  Comparing between the Well-Whole and 
Well-Spot configurations, the Well-Whole format offers simpler assay protocol and the 
detection limit is lower with the current measurement setup.  For this work, it should be 
noted that for applications that have high sensor response levels or where the sensor 
measurement response time is not an issue, microfluidic based devices do not require 
consumption of large quantities of reagents in comparison to the microplate format.  A 
comparison of the four assay formats investigated in this work is shown in Table 2.1. 
 




Four different combinations of bioassay formats and capture molecule 
immobilization methods were investigated through the use of label-free PC biosensors.  
The assay platforms investigated were the PC biosensor integrated microfluidic device 
with capture antibody spots immobilized local to the detection area (Channel-Spot), 
microfluidic sensor device with the entire surface immobilized with capture antibodies 
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(Channel-Whole), a standard 384-microplate based PC biosensor with capture antibody 
spots in the well (Well-Spot), and the same 384-microplate sensor with the entire bottom 
surface immobilized with capture antibodies (Well-Whole).  FEM simulation was utilized 
to model the biomolecular binding kinetics occurring in the different assay platforms, and 
the results from the model were verified experimentally through the protein-protein 
binding affinity assay using TNF-α and anti-TNF-α.  The simulation model was then used 
to predict the equilibrium sensor response, sensor measurement time required to reach the 
equilibrium levels, and the detection limit of the TNF-α protein binding assay, taking into 
account the conditions for each of the four assay formats.  The results were then used to 
compare the assay performance for each of the assay methods.  The microfluidic-based 
formats (Channel-Spot/Channel-Whole) offered fast detection time, the greatest 
equilibrium binding of analyte, and lowest detection limit.  In addition, the reaction rate 
constants of biomolecular interaction could be measured.  The Well-Spot device offered 
the lowest ligand consumption with low analyte volume and has the potential for lower 
detection limit as its equilibrium analyte binding level was similar to that of the 
microfluidic-based formats.  The Well-Whole format offered low analyte consumption 
with a simple assay protocol.  The assay performance results for different platforms 
obtained from the work in this chapter are applicable to any label-free biosensor system 
based on surface detection where analyte molecules are brought into contact with the 
capture molecule immobilized on the sensor surface. 
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CHAPTER 3: MICROFLUIDIC CHIP FOR COMBINATORIAL MIXING AND 
SCREENING OF ASSAYS 
3.1 Introduction 
Microfluidic approaches have been utilized for a wide range of applications 
including analysis, diagnostics, synthesis, and drug discovery [58-61].  Previous efforts 
for combinatorial mixing and analysis have focused on continuously flowing microfluidic 
systems [62-64].  Mixing is performed either by diffusion between contacting streams or 
by merging droplets in segmented flow, while analysis is performed externally by 
GC/MS or MALDI-MS.  Due to the serial nature of the analyses in these continuously 
flowing systems, volumes are limited to the nanoliter range, and the complexity of the 
reaction schemes is limited.  To further reduce volume while achieving increased reaction 
complexity, a finely controlled microfluidic approach that allows for on-chip analysis is 
required.  
 In prior work the use of photonic crystal (PC) biosensors was demonstrated as a 
highly sensitive label-free detection method for performing a wide variety of biochemical 
and cell-based assays [15, 65].  The sensor surface is designed to reflect only a narrow 
band of wavelengths with close to 100% efficiency when illuminated with white light at 
normal incidence.  A shift of the reflected peak wavelength value (PWV) to longer 
wavelengths indicates adsorption (e.g. binding) of a molecular species on the sensor 
surface.  Recently, these label-free PC biosensors were integrated into polymeric 
continuous flow microfluidic systems [14, 16, 25].  For example, integration of flow 
channels that originate at individual wells and converge on a row of PC biosensors within 
a standard 96-well microplate format enabled continuous sampling of each well [22].  
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This approach was used to determine the binding kinetics of biomolecular interactions.  
In other work, the ability to detect small molecule binding was also demonstrated with 
PC biosensors [66].  This PC biosensor-based technology could be greatly enhanced if 
combined with a mechanism for synthesis and screening of combinatorial arrays of small 
molecules, a highly desired capability for a wide range of screening applications.  A 
novel platform with these capabilities would require further reduction of reagent volumes 
and active, parallel fluid handling to create the combinatorial arrays, while retaining on-
chip analysis capabilities. 
 The advent of microfluidic networks with vast arrays of valves by Quake and 
coworkers [67, 68] has enabled massively parallel chemical syntheses and biological 
studies in very small volumes (nL – pL), e.g., protein crystallization screening tools [69] 
and microfluidic gene expression profiling [61].  These chips are typically fabricated via 
multi-layer soft lithography, the assembly of multiple polydimethylsiloxane (PDMS) 
membranes that have microscale channels embossed in their surface as negative relief 
features.  Microchannels in the so-called fluid layer are pneumatically filled with liquid 
using pressurized external feed lines, while microchannels in the so-called control layer 
are pneumatically actuated at a higher pressure to actively close off fluid lines that they 
cross at certain locations (Actuate-to-Close or AtC valves).  While elegant in routing 
liquid quanta in microfluidic networks, some aspects of this approach are less desirable 
with respect to integration of sensing capabilities and the creation of combinatorial arrays.  
AtC-valve based chips require careful pressure balancing between fluidic and control 
lines, and with the AtC valves requiring continuous actuation to stay closed, the fluidic 
layer must be permanently sealed to a substrate to avoid leaking.  Furthermore, the chip 
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continuously must be connected to an external pressure source, which limits portability of 
the chip, e.g. between a filling station and detection ancillaries.  
 As an alternative to AtC valves, Mathies has reported the integration of valves 
that require vacuum actuation of a flat commercially available PDMS layer sealed 
between two glass slides with channels etched into both layers [70].  These valves can be 
utilized in multiplexed arrays [71] and have the distinct benefit of being closed at rest.  
Like the AtC valves above, irreversible sealing is required for operation.  Further 
increasing the number density of these valves, as required for massively parallel 
combinatorial applications, would be challenging. 
 In contrast to the above approaches, the implementation of massive arrays of 
vacuum-actuated Actuate-to-Open (AtO) valves in elastomeric microfluidic networks, 
which greatly simplifies chip operation and handling, is described in this chapter.  To 
highlight the benefits of this approach, a microfluidic chip capable of metering and 
mixing a combinatorial array of 200 pL volumes of A × B reactants, resulting in A1B1 to 
ANBN combinations that are isolated in individual wells, is created.  The bottom surface 
of each well is equipped with a PC biosensor enabling in situ detection of biomolecular 
interactions in each well. 
 
3.2 Materials and Methods 
3.2.1 Actuate-to-open valve arrays 
In these chips a control layer and fluid layer are utilized similar to microfluidic 
networks with AtC valves [68], but fluid lines and compartments are isolated because the 
AtO valves are passively closed at rest (Figure 3.1).  The actuation chamber of an AtO 
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valve in the control layer is located directly over a small barrier in the fluid layer that 
separates adjacent compartments or channels.  Upon actuation of the control layer 
compartment with a negative pressure (on the order of 10 psig below ambient), these 
barriers are lifted to open pathways for fluid routing within the chip.  Liquid can be 
pumped into the chip by applying a negative pressure at an opposing outlet.  In addition, 
liquid can be pulled into a dead-ended channel because actuation of the AtO valves 
gradually removes trapped air in the fluid channel through the gas-permeable PDMS 
membrane into the control layer.  After the negative pressure is released, the barriers 
between compartments collapse shut, back into the rest state.  The pneumatic lines can 
then be disconnected from the chip without affecting the sealed, reagent-filled 
compartments within the chip. 
 
Figure 3.1  Schematic of an Actuate-to-Open (AtO) valve comprised of a pneumatic control layer and 
a fluid layer, placed on a PC biosensor patterned on a glass substrate.  Actuation by applying a 
negative pressure (right) lifts the barrier between adjacent compartments, allowing for fluid flow.  
After release of the negative pressure the valve collapses to the closed rest state (left). 
 
 As mentioned above, a pressure of about -10 psig is needed to overcome the 
adhesion between the valve seat and the glass surface, thereby opening the AtO valves.  
A much lower pressure, down to -1 psig is sufficient to keep AtO valves open.  In the rest 
state (closed), the AtO valves can easily sustain liquid pressures up to 10 psig. 
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 The use of AtO valves as opposed to AtC valves in elastomeric microfluidic 
networks has many advantages:  (i) AtO valves are closed when at rest, the state most 
valves are in most of the time in just about any application.  Compared to the AtC valves, 
this eliminates the need for continuous actuation at pressures of 5 to 30 psig.  (ii) They 
eliminate the need for irreversible sealing of the fluid layer to a bottom substrate such as 
a sensor surface (Figure 3.2a).  (iii) The gas permeable properties of PDMS eliminate the 
need for reagent feed lines as fluids are pipetted over inlet ports and are pulled into the 
fluid lines upon actuation of AtO valves, dramatically reducing dead volume (Figure 
3.2b).  (iv) In stark contrast to AtC valve-based chips, an AtO chip is highly portable 
since it can be disconnected from all lines after filling, and moved to a detection platform 
(e.g. microscope, plate reader).  (v) The AtO valve design affords a higher degree of 
complexity, i.e. a higher density of compartments per unit area because valve area 
overlaps with compartment area as opposed to being located between compartments. 
Constant pneumatic actuation is not required for AtO-based microfluidic systems, 
making them more amenable for field-portable applications.  The absolute pressures 
needed to actuate AtC or AtO valves are similar and can be achieved in a portable device, 
for example, using gas tight syringes.  However, AtO valves only need to be actuated 
briefly during filling of a chip (typically less than 30 sec), whereas AtC valves need to be 
actuated over the course of an experiment (e.g., an incubation over several min to hr) in 
order to maintain the liquids confined in separate compartments.  The gas permeable 
nature of the PDMS leads to a gradual loss of pressure on AtC valves which a 
comparably portable system would need to account for. 
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Figure 3.2  (a) Optical micrograph of a 4 × 4 microfluidic chip placed on a patterned array of 
biosensors.  Each well is comprised of two adjacent compartments, each with its own biosensor (dark 
circles).  (b) Photograph of the multilayer microfluidic array chip. Dyed droplets are pipetted at the 
inlet ports and sucked into the columns by actuation of the appropriate set of valves.  (c) Optical 
micrograph of a 4 × 4 array of wells, highlighting the fluidic layer: the 4 rows and 4 columns are each 
filled with an aqueous solution of different color to show the combinatorial generation of 16 different 
combinations of reagents.  (d) Optical micrograph of a 4 × 4 array of wells, highlighting the control 
layer: The 3 sets of valves control filling of the horizontal rows (black squares), filling of the vertical 
columns (orange rectangles), and the mixing of reagents in adjacent compartments (red squares).  (e) 
Close-up of an individual well in the chip at the very onset of mixing (valve actuated).  (f) Mixing is 
completed following repeated valve actuation over 3 – 5 min. 
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3.2.2 Design and fabrication of the PC biosensor array chip 
A 4 × 4 microfluidic well plate with combinatorial mixing and sensing 
capabilities was created enabled by the use of AtO valves (Figure 3.2a, b).  Each well is 
comprised of two U-shaped, 200-pL compartments (Figure 3.2c, e).  Three separate sets 
of AtO valves control bi-directional filling and mixing of all 16 wells.  The reagents (2 
L each) are pipetted at the inlets of each of the four rows and four columns.  Then 
actuation of the first set of valves (Figure 3.2d, black squares) initiates horizontal flow, 
filling the rows comprised of the right compartment of each well.  Subsequent actuation 
of the second set of valves (Figure 3.2d, orange recatngles) initiates vertical flow, filling 
the columns comprised of the left compartment of each well.  Upon releasing pneumatic 
actuation, all valves collapse into their rest state, thereby isolating the reagents in their 
individual U-shaped compartments.  Next, by actuation of the third set of valves (Figure 
3.2d, red squares), reagents in all 16 sets of two adjacent U-shaped compartments are 
mixed.  Mixing occurs by diffusion and convection upon 8 – 15 valve actuations and 
relaxations over the course of 3 – 5 min, as demonstrated with dyes (Figure 3.2e, f). 
 Next a patterned 4 × 4 array of two circular PC biosensors (D = 250 µm) was 
fabricated on glass (Figure 3.2a).  The porous, dielectric-based PC biosensor gratings 
were obtained via replica molding as reported previously [14], and photolithography was 
used to create the patterned array of circles.  This pattern exactly maps on the dimensions 
and relative spacing of the U-shaped compartments of the fluid layer and avoids intra-
well leaking, which occurred initially along the grating ridges when using unpatterned, 
uniform PC biosensor substrates. 
 57 
 
3.2.3 Imaging detection instrument 
The high resolution imaging detection instrument used for the binding assay was 




3.3.1 Binding assay 
To demonstrate the combinatorial capabilities of the PC biosensor array chip, a 
proof-of-principle protein/antibody binding assay was performed.  The high sensitivity of 
the PC biosensors requires a method that effectively distinguishes nonspecific binding of 
antibodies to a sensor surface from an antibody adhering to a specific, surface-
immobilized protein.  To that end, an experimental and a control compartment were 
incorporated for each well within the array, with each compartment having its own PC 
biosensor.  Reagents were introduced into the microfluidic network by actuation with a 
negative pressure, and when the AtO valves were relaxed, all compartments were sealed 
off, so the chip could be transported for further analysis. 
 For the binding assay experiment, proteins A and A/G (Pierce Biotechnology) at 
0.5 mg/mL in phosphate buffered saline (PBS, Sigma-Aldrich), were incubated for 10 
min in the experimental compartments (2nd, 4th row of Figure 3.2c).  Sea Block (Pierce 
Biotechnology) diluted in PBS to 20% by volume was then incubated for 10 min across 
all compartments as a preventative measure against nonspecific binding.  Subsequently, 
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all compartments were rinsed with PBS; and goat, chicken and human immunoglobulin G 
(IgG) antibodies (Sigma-Aldrich) at a concentration of 0.5 mg/mL in PBS were incubated 
for 10 min in the control compartment of each well within the 2nd, 3rd and 4th columns.  
PBS was introduced in the 1st column as an additional control.  After introducing 
antibodies, the valves were disconnected from the pneumatic lines and relaxed to the 
closed rest state, sealing off all filled compartments. 
 At this point, each well contained either PBS or an antibody solution in the left 
(control) compartment, and PBS in the right (experiment) compartment.  The chip was 
disconnected from all pressure lines and a background scan was taken to record the index 
of refraction of PC biosensors covered with certain proteins and in the presence (or 
absence) of certain antibodies in PBS.  Next, the chip was reattached to the negative 
pressure source, and the contents of adjacent control and experiment compartments were 
mixed by actuation of the mixing valves as explained above (Figure 3.2e, f).  A 30-min 
incubation period with the mixing valve open followed, allowing the antibodies to 
equilibrate with the surface-immobilized proteins, particularly those in the experiment 
chamber.  The chip was disconnected from the vacuum source and a final scan of the 
whole array was taken.  Subtraction of the background yielded the binding assay results 
shown in Figure 3.3.  Red color indicates strong binding between a given protein and 
antibody combination.  The lack of red coloring in the internal controls, as well as in the 
microfluidic rows and columns containing only PBS, indicates lack of nonspecific 
binding as well as a lack of intra-compartmental leaking, which should have been 
immediately noticed with the protein-antibody assay with the high binding affinities used 
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here.  While the polymeric device is only reversibly sealed to the sensor surface, the AtO 
valves at rest were sufficient to prevent leaking. 
 
Figure 3.3  On-chip binding assay between proteins (A and A/G) and antibodies (goat, chicken and 
human).  The binding experiment between each protein-antibody combination takes place in the 
circled compartment on the right of each well, which is compared against a control compartment to 
its left to rule out nonspecific binding of antibodies.  Red coloring within these circles indicates a shift 
in the PWV, indicative of a binding event. 
 
 Finally, the data was analyzed to quantify the extent of binding for each protein-
antibody combination.  The pixels within each experiment compartment (indicated by the 
circles in Figure 3.3) were averaged to a single PWV shift value.  An average PWV shift 
for each protein-antibody combination was obtained by subtracting the average PWV of a 
control compartment from the average PWV of each adjacent experiment compartment to 
account for signal drift across the array (Figure 3.4).  The measured PWV shift values 
obtained here are consistent with protein/IgG binding experiments previously published 
[25] where human IgG has a strong binding affinity for both protein A and A/G, goat IgG 
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has weak binding affinity for protein A but strong affinity for protein A/G, and chicken 
IgG lacks binding affinity with either protein A nor A/G. 
 
 
Figure 3.4  Analysis of PWV shifts observed in on-chip binding assay.  As expected, human IgG 
bound strongly to protein A and protein A/G, while goat IgG had a weaker affinity for these proteins. 




The design and fabrication of a microfluidic array chip with combinatorial mixing 
and on-chip sensing capabilities was demonstrated.  A combinatorial matrix of reactions 
could be performed within 200 pL microfluidic compartments that could be sealed 
reversibly to a patterned PC biosensor for the determination of binding events.  The 
ability to decouple such AtO-valve based chips from an external pressure source, while 
retaining the reagents locked up in isolated compartments, greatly simplified their use, 
particularly for sensing purposes that need to be performed away from fluidic handling 
capabilities.  Current valving technology cannot accomplish this level of post-mixing 
portability at such high densities.  A common problem associated with reversibly sealed 
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microfluidic chips is their propensity to leak, but the proof-of-principle reaction scheme 
shown in this chapter using IgG-antibodies demonstrated that AtO-based microfluidic 
networks do not suffer from leaking issues.  Binding events properly correlated to 
expected results, showing a high fidelity within wells despite the reversible seal.  The 
ability to perform these reactions reliably at such small scales with such ease of use 
would serve as a great advantage in performing vast array chemistries using much 
smaller amounts of reagent in combinatorial matrices than presently used in traditional 
micro-titer plate approaches.  Furthermore, the inherent ability of PC biosensors to detect 
small molecule binding events [66] is preserved in the microfluidic platform presented in 
this chapter.  This microfluidic array chip is thus a promising candidate for chemical 
synthesis and combinatorial screening applications where multiple steps have to be 
carried out in parallel in minimal reagent volumes.  
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CHAPTER 4: SURFACE-ENHANCED RAMAN SCATTERING NANODOME 
ARRAY 
4.1 Introduction 
 Due to its capability for specific chemical identification through measurement of 
vibrational energies associated with chemical bonds in molecules, Raman spectroscopy is 
a powerful and versatile method for label-free molecular identification. As a general 
purpose analytical method, the applications for Raman spectroscopy span a broad range 
of fields that includes protein-protein interaction analysis, DNA/RNA hybridization, 
aptamer conformational change, viral particle detection, bacteria identification, and 
detection of explosives [72-77].  As first observed by Fleischmann and discovered by 
Van Duyne, the extremely small Raman scattering cross section may be enhanced when a 
molecule is in close proximity to a roughened metal surface that supports regions of 
heightened electromagnetic field intensity [78, 79].  The first demonstrated surface-
enhanced Raman spectroscopy (SERS) substrates, providing enhancement factor of ~10
6
, 
were made from electrochemically roughened silver electrodes produced by repeated 
oxidation-reduction cycles [78-81].  The SERS enhancement factor enables Raman 
scattering spectra to be gathered rapidly with substantially less laser power, resulting in 
many detection applications becoming more feasible, provided that the analytes have an 
opportunity to come into contact with the SERS-active surface. 
In recent years, with advancements in nanofabrication technology and the broad 
availability of computer simulation tools that enable investigation of the interactions of 
metal/dielectric nanostructures with electromagnetic fields, a wide variety of nanoparticle 
shapes and structures have been demonstrated as SERS-active surfaces with greater 
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enhancement factors.  For example, colloidal metal (silver or gold) nanoparticle clusters 
of size ranging from 100 to 150 nm, dispersed in solution, have been used to achieve 
single-molecule SERS detection, with reported enhancement factors as high as ~ 10
15
 [82, 
83].  Nanoparticles with sharp tips, such as metallic  “nanocrescents,” have demonstrated 
enhancement factors of > 10
10
 through the effects of electromagnetic field focusing into a 
small volume when the particle couples with an externally applied laser source through 
surface plasmons [84].  While SERS approaches using colloidal metal aggregates can 
produce large enhancement factors, their use is limited due to the lack of enhancement 
factor reproducibility and low overall “hot-spot” volume density stemming from their 
sensitivity to random nanocluster morphology [85, 86].   
 Compared to SERS-active nanoparticles suspended in solution, SERS-active 
surfaces can be fabricated with engineered three-dimensional topologies using a wide 
variety of lithography approaches to precisely define desired features.  SERS surfaces are 
especially desirable in applications for which one wishes to measure Raman spectra 
without adding nanoparticles to a test sample, and for multiplexed arrays of Raman 
measurements.  For example, using electron-beam lithography to fabricate uniform, 
closely spaced metal nanoparticle arrays of circular, triangular, and square shapes, with 
interparticle spacing of 75 – 250 nm,  reproducible SERS enhancement factors of ~ 106 
have been demonstrated [87-90].  Recently, electron-beam lithography patterning of 
arrays of 200 nm diameter gold nanocylinders has been combined with gold chemical 
reduction to create “plasmonic nanogalaxy” substrates that exhibit a cascade 
enhancement effect to generate a spatially averaged SERS enhancement factor up to ~10
8
 
[91].  Although large enhancement factors can be achieved using the high resolution 
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capabilities of  electron-beam lithography, the applications of such devices are limited 
due to the time (and associated cost) of producing such structures over surface areas 
greater than a few square millimeters.  For this reason, there has been intense research 
interest in the development of processes for creating SERS substrates with a high density 
of electromagnetic hot spots using procedures that are more amenable to low-cost and 
large-area fabrication.  For example, a soft lithographic molding technique was used to 
fabricate SERS plasmonic crystals on ~ 20 × 20 mm
2
 area and nanowell structure 
integrated with microfluidic network on a 4 inch wafer, demonstrating enhancement 




, respectively [92, 93].  Nanoparticle dimer arrays fabricated by a 
combination of nanoimprint soft lithography and meniscus force deposition have been 
demonstrated on a 5 in wafer with enhancement factor up to 10
9
 [94].  Likewise, 
nanosphere lithography (NSL) and metal film over nanosphere (MFON) structures are 
effective SERS substrates in which arrays of metal triangles (for NSL) or metal domes in 
a periodic hexagonal lattice (for MFON) are created by deposition of metal thin films 
over a monolayer of close-packed polymer spheres [95, 96].  MFON has demonatrated 
SERS enhancement factors of up to 10
7
 on substrates with diameter reported as large as 
18 mm [97, 98].  Uniform patterning of the MFON surface is dependent upon the ability 
to produce a defect-free monolayer of ~ 500 – 600 nm diameter polymer or silica spheres 
using processes such as drop coating, spin casting or controlled withdrawal of the 
substrate from a liquid bath. 
Nanoreplica molding has been demonstrated as a low-cost method for 
manufacturing periodic surface structures for a variety of applications. The method is 
performed using low force at room-temperature to produce nanometer scale structures 
 65 
with high uniformity over a large surface area using a patterned silicon wafer as a 
reusable molding template.  The area of nanoreplica molded surfaces is ultimately limited 
only by the size of the silicon wafer.  However, the process has been adapted for 
fabrication upon continuous sheets of flexible plastic film in a roll-to-roll process that is 
capable of producing nanostructured surfaces on the scale of square meters [12].  
Nanoreplica molding has been demonstrated for a variety of devices, including photonic 
crystal label-free biosensor microplates [34, 99], photonic crystal enhanced fluorescence 
microscope slides [100, 101], distributed-feedback laser biosensors [102], tunable optical 
filters [103], scaffolds for cartilage engineering [104], microplasma displays [105], and 
microfluidic channels [22, 25, 56].  In this chapter, a SERS active substrate comprised of 
a close-packed array of ~ 311 – 377 nm diameter dome structures is demonstrated.  The 
structure is fabricated by a process that combines nanoreplica molding and unpatterned 
blanket deposition of SiO2 and Ag thin films.  The thin film deposition process is used to 
control the spacing between adjacent domes with nanometer-scale precision to provide a 
uniformly distributed array of SERS hot spots that can be produced over a large surface 
area.  An enhancement factor of 10
8
 is demonstrated within the hot spot regions, resulting 
in an enhancement factor of 10
6
 when the enhancement is averaged over the entire 
available surface area. 
 
4.2 Materials and Methods 
4.2.1 Nanoreplica molding process 
A process flow diagram is shown in Figure 4.1.  First, nanoimprint lithography 
(NIL) (Molecular Imprints) and reactive ion etching were used to pattern an 8 inch (200 
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mm) silicon wafer with a 2-dimensional array of 300 nm diameter holes (period = 400 
nm, depth = 130 nm), in 8 × 8 mm
2
 dies to produce a mold template with overall feature 
dimensions of 120 × 120 mm
2
. The completed silicon mold template was subsequently 
treated with dimethyl dichlorosilane (GE Healthcare) to promote clean release of the 
replica (Figure 4.1a).  Next, a negative volume image of the silicon surface structure was 
replicated onto a flexible polyethylene terephthalate (PET) substrate by distributing a 
layer of liquid UV curable polymer (Gelest, Inc.) between the silicon wafer and the PET 
substrate. The liquid polymer conforms to the shape of the features on the wafer, and is 
subsequently cured to a solid state by exposure to a high intensity UV lamp (Xenon Inc.) 
at room temperature (Figure 4.1b).  After curing, the molded structure was released from 
the wafer by peeling away the PET, resulting in a polymer replica of the silicon wafer 
structure adhered to the PET sheet (Figure 4.1c).  The replica molding process results in 
the formation of a rectangular array of ~ 130 nm-tall polymer cylinders that are separated 
by ~ 110 nm at their outer perimeters.  In order to produce a SERS active surface with 
metal nanostructures that are separated by distances smaller than 110 nm, SiO2 was 
applied over the polymer cylinders by electron-beam evaporation (Figure 4.1d).  Through 
control of the deposited SiO2 thickness (SiO2 films of 0, 50, 75, 100, and 125 nm were 
investigated), the cylindrical polymer surface evolves into a dome structure with a radius 
that increases with SiO2 thickness.  SiO2 deposition is followed by application of a 200 
nm silver thin film by electron beam evaporation to complete the device (Figure 4.1e).   
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Figure 4.1  Cross section diagram of the nano-scale replica molding process.  (a) Fabrication of 
silicon master wafer template with 400 nm period 2-dimensional circular hole structure using 
nanoimprint lithography (NIL) and reactive ion etching to a depth of 130 nm.  (b) Distribution of 
liquid-state UV curable polymer between the silicon master wafer and the PET substrate with 
subsequent solidification by UV light exposure.  (c) Release of the PET substrate, resulting in a 
polymer replica of the silicon wafer structure adhering to the PET sheet.  (d) – (e) Deposition SiO2 
followed by Ag on the replicated surface using electron beam evaporation. 
 
The SiO2 thickness was used to control the nanodome separation distance, which 
is the most important variable for determination of the SERS enhancement factor.  
Scanning electron microscope (SEM) images of the fabricated SERS substrates are 
shown in Figure 4.2.  The SEM images were used to measure the separation distance 
between adjacent domes, resulting in the relationship shown in Figure 4.3.  For SiO2 
thicknesses of 0, 50, 75, 100 nm, the separation distance for the nanodome arrays were 
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84, 59, 33, and 17 nm with the nanodome base diameters of 311, 344, 363, and 377 nm, 
respectively.  When the SiO2 thickness exceeded 100 nm, the dome spacing reduced to 
zero, resulting in domes that touch each other, as shown in Figure 4.2e.  SEM 
measurements confirmed that the replica molded structures have a period of 400 nm, as 
would be predicted by the period of the silicon mold template. 
 
Figure 4.2  SEM images of nanodome array substrates.  (a)  Ag coated nanodome array substrate 
with measured separation distance of 17 nm.  (b) Close-up view of the nanodome array in (a).  (c) 
Tilted view of nanodome array substrate in (a) and (b).  (d) Ag coated nanodome array substrate 
with measured separation distance of 84 nm.  (e) Ag coated nanodome array substrate with domes 




Figure 4.3  Plot of the measured nanodome separation distance (red squares, left axis) and diameter 
(blue circles, right axis) as a function of SiO2 thickness deposited on the replica. 
 
4.2.2 Computational analysis of field distribution and Raman enhancement 
Since the discovery of the SERS phenomenon, two main enhancement 
mechanisms have been proposed: the chemical enhancement effect and the 
electromagnetic enhancement effect [81, 106].  Of the two mechanisms, it is believed that 
the SERS enhancement is dominated by the electromagnetic mechanism, which is due to 
the enhanced electromagnetic fields originating from the localized surface plasmon 
resonance (LSPR) effect on both the incident laser and the Raman scattered radiation 
from the analyte molecules on metal nanostructures.  The theoretical SERS enhancement 






























where )( exlocE    is the amplitude of the LSPR enhanced local electric field at the laser 
wavelength, )(0 exE   is the amplitude of the incident electric field (provided by the laser) 
at the laser excitation wavelength, )( slocE   is the amplitude of the enhanced local electric 
field at the Raman scattered wavelength, and )(0 sE   is the amplitude of the electric field 
at the Raman scattered wavelength (radiated by the analyte molecules).  
In order to investigate the characteristics of the nanodome array structure as a 
SERS substrate and to study the effect of inter-dome separation distance on the SERS 
enhancement (Equation 4.1), finite element method (FEM) modeling using a 
commercially available software package (COMSOL Multiphysics) was utilized to map 
the electric field distribution around the nanodomes.  The result of the 3-dimensional 
simulation of the electric field distribution between two adjacent nanodomes within the 
array is shown in Figure 4.4a with the scale bar on the right side representing the 
normalized amplitude of the scattered electric field with respect to the incident electric 
field amplitude.  The regions of enhanced electric field are clearly visible in the area 
between adjacent nanodomes where the separation distance is minimal, as expected due 
to the coupling effect of LSPR field enhancement.  To approximate the conditions in our 
measurement apparatus, the nanodome arrays in the simulation were excited with a 
normally incident plane wave at λ = 785 nm, propagating in the –z direction with linear 
polarization in x direction.  The simulation was performed by approximating the metal-
coated nanodome structure as having a hemispherical contour.  The nanodome array was 
modeled as a dimer structure with symmetric boundary conditions on the sidewalls of the 
simulation boundary, in order to reduce the computational load.  Figure 4.4b shows the 
maximum values of Raman enhancement calculated using Equation 4.1 and the FEM 
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modeled electric field distribution for the laser excitation and the Raman scattered 
wavelength corresponding to wavenumber shift of ~ 1370 cm
-1 
for nanodome arrays of 
inter-dome separation distances of 17, 33, 59, and 84 nm, to match the spacings measured 
by SEM. 
 
Figure 4.4  (a) 3-dimensional FEM simulation of the electric field distribution around the Ag 
nanodome particles.  Scale bar on the right side represents the normalized amplitude of the scattered 
electric field with respect to the incident electric field amplitude.  The nanodome arrays were excited 
with an incident plane wave at λ = 785 nm, propagating in the –z direction with linear polarization in 
x direction.  The nanodome array was modeled as a dimer structure with symmetric boundary 
conditions on the sidewalls of the simulation boundary.  (b) Maximum Raman enhancement 
calculated from the FEM simulation of electric field distribution around the nanodome array for the 
laser excitation (λ = 785 nm) and the Raman scattered wavelength corresponding to wavenumber 
shift of ~ 1370 cm
-1 




4.3.1 Experimental SERS measurement 
In order to experimentally verify the effect of nanodome spacing on SERS 
intensity, 1 μM rhodamine 6G (R6G) solution was applied to each substrate.  The Raman 
measurement was performed using a 30 mW laser operating at λ = 785 nm, which was 
focused on the substrate surface by a 10× objective lens (NA = 0.28), resulting in a probe 
spot radius of 10 μm.  SERS photons were collected by the same objective lens, using an 
integration time of 1 sec.  Figure 4.5 shows the experimentally measured relative SERS 
intensity, defined as )()( maxdIdI  where maxd = 84 nm, of the substrates as a function of 
nanodome separation distance d  plotted as black hollow dots.  The SERS intensity 
values were measured at Raman peak corresponding to a wavenumber shift of 1370 cm
-1
.  
The error bars in the figure represent ± 1 standard deviation of the relative intensity 
obtained throughout five nanodome array substrates for each inter-dome separation 
distance.  Also plotted in Figure 4.5 are the FEM-simulated relative SERS enhancement 
values with respect to the dome separation distance marked as red squares.  As shown in 
Figure 4.5, SERS intensity/enhancement dependence on inter-dome separation shows a 
very good agreement between the experimentally measured and simulated values.  The 
inset in the figure shows example SERS spectra for devices with different separation 
distances ranging from 17 to 84 nm.  The SERS intensity observed from the experiment 
demonstrates that SERS enhancement is very sensitive to inter-dome spacing, and 
suggests that even higher enhancements may be achievable by controlling the spacing 
below 17 nm.  Interestingly, when adjacent nanodomes are allowed to touch each other (d 
= 0 nm), the enhancement abruptly drops down to the same value obtained when the 
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inter-dome spacing is large.  This suggests that the majority of the enhancement comes 
from the “hot spot” region located in the volume region between adjacent nanodomes 
with enhanced electromagnetic field intensity from inter-dome near-field interaction, 
consistent with the electric field distribution obtained from the FEM model. 
 
Figure 4.5  Plot of relative SERS intensity I(d)/I(dmax = 84 nm) as a function of nanodome separation 
distance, d, for 1 μM R6G, measured at the Raman peak corresponding to a 1370 cm-1 wavenumber 
shift.  Experimentally measured relative SERS intensities are marked as black hollow dots with error 
bars representing ± 1 standard deviation for five nanodome array substrates for each dome 
separation distance (N = 5).  Relative SERS enhancement values obtained from the FEM simulation 
are plotted as red squares.  The inset shows example SERS spectra for the nanodome array 
substrates with different d values ranging from 17 to 84 nm. 
 
4.3.2 SERS enhancement factor measurement 
In order to experimentally measure the SERS enhancement factor for the 
nanodome array substrates, a concentration series of R6G molecules (1 nM – 10 μM) 
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were deposited on SERS sensor surface with an inter-dome separation distance of d  = 17 
nm.  To serve as a reference, 1 mM R6G was also deposited on the same substrate in the 
area outside of the nanodome region.  Using the same detection instrumentation and 
measurement parameters outlined previously, the SERS spectra shown in Figure 4.6 were 
obtained. 
 
Figure 4.6  SERS spectra of R6G molecules ranging from 1 nM to 10 μM on the nanodome array 
substrate with d = 17 nm and 1 mM R6G on the reference surface without the nanodome array.  (The 
reference spectrum was multiplied by a factor of 5 in the plot.) 
 












where SERSI  is the surface enhanced Raman intensity, surfN  is the number of molecules 
within the enhanced field region of the metallic substrate contributing to the measured 
SERS signal, refI  is the Raman intensity from the reference region, and bulkN  is the 
number of molecules within the excitation volume of the laser spot for the analyte on the 





where r  is the radius of the excitation laser spot (10 μm), h  is the thickness of the R6G 
spot on the reference region (0.72 µm), c  is the molar concentration of the R6G analyte 
on the reference region (1 mM), and AN  is the Avogadro’s number.  surfN  was defined to 
be the number of molecules occupying the volume of the “hot spot” region with high 
enhancement of the local electric field.  The volume of the hot spot region for calculation 
of surfN  was determined from the FEM simulation of the electric field distribution where 
the enhanced signal was assumed to take place within the region bounded by the volume 
within which the exponentially decaying enhanced electric field is reduced by a factor of 
1/e.  Using the SERS intensity from the 1370 cm
-1
 peaks of 1 nM R6G on the SERS 
active region and 1 mM R6G on the reference region for SERSI  and refI , respectively, the 
SERS EF was calculated to be 1.37 × 10
8
.  The preceding calculation of enhancement 
factor describes only the enhancement that occurs within the region of highest electric 
field, and does not account for the fact that only a portion of the available surface area of 
the substrate is supporting an elevated electric field.  To take into account the volume 
(4.3) 
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density of hot spots, the spatially averaged EF can also be calculated.  For spatially 
averaged EF, all analyte molecules within the excitation laser spot volume are assumed to 
contribute equally to the measured SERS signal.  The spatially averaged EF, which 
represents an underestimation of the local EF from Equation 4.2, provides a more 
practical, experimentally measured value of the SERS enhancement.  The spatially 






In this chapter, a SERS substrate consisting of a closely spaced array of metal-
coated dielectric nanodomes fabricated utilizing a low-cost, large-area nanoreplica 
molding method was demonstrated.  During the fabrication process, the inter-dome 
spacing was precisely controlled through the thickness of SiO2 and Ag thin films 
deposited over a replica molded array of polymer cylinders.  FEM simulation was used to 
investigate the electromagnetic field distribution between adjacent nanodomes, where 
excellent agreement between the experimentally measured and simulated values for the 
intensity/enhancement dependence on inter-dome spacing was obtained.  Experimentally 
measured SERS enhancement factor on the order of 1.37 × 10
8
 was demonstrated for the 
SERS substrate presented in this work.  The nanorepolica molding process allows simple, 
low-cost fabrication of the required surface features over a large area, providing a path 
towards mass production of SERS substrates with high enhancement factor. 
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CHAPTER 5: BIOCHEMICAL SENSOR TUBING FOR POINT-OF-CARE 
MONITORING OF INTRAVENOUS DRUGS AND METABOLITES 
5.1 Introduction 
In 2008, over 350,000 Americans used dialysis to supplement their kidney 
function and this number is expected to grow substantially in the future, as > 26 million 
Americans have chronic kidney disease (CKD) as a result of diabetes and high blood 
pressure [109, 110].  At the same time, a wide range of drugs and fluids are administered 
to millions of patients each year using pumped intravenous (IV) delivery, often in 
combinations used to treat multiple conditions at once.  Within the intensive care unit of 
hospitals, bedridden patients are routinely fitted with urinary catheters that allow drainage 
of their bladders, and laboratory-based tests are performed upon urine samples to 
periodically monitor the concentrations of excreted metabolites. 
A characteristic that is shared by all three of these common medical practices is 
the use of disposable sterile plastic tubing to transfer fluids to or from a patient.  As the 
US health care industry seeks to more effectively provide medical treatment, the concept 
of an “intelligent” system that gathers sensor readings from bodily fluids and provides 
accurate and timely information on the status of a patient, or that can reduce errors in 
medication delivery, has gathered momentum [111-113].  However, an important 
bottleneck to the translation of such systems to clinical practice has been the prohibitive 
cost/complexity of sensors, and their lack of compatibility with the fluid handling 
methods commonly used in hospitals.   
Detection and identification of the chemical or biological contents of fluid within 
a flow stream is a critical component of systems used for medical diagnosis and 
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medication delivery.  For example, in-line monitoring of the components of bodily fluids, 
such as blood and urine, has become a priority in clinical care.  In some situations, such 
as dialysis, a bodily fluid may be analyzed before and after an ex-vivo filtration process 
in which the fluid will be returned to the patient’s body.  Likewise, the ability to 
continuously monitor the contents of an IV line being used to deliver medication to a 
patient for validation of the desired drug and the presence of contaminants (both chemical 
and bacterial) would offer a means for minimizing medication errors while at the same 
time detecting the onset of infections before they become life-threatening.  In a similar 
fashion, the ability to continuously monitor the chemical contents of urine flowing 
through a catheter would enable noninvasive monitoring of well-established chemical 
biomarkers for renal function and metabolism.   
For detection and identification of analytes in a clinical setting, it is not generally 
permissible to introduce materials such as chemicals, enzymes, or nanoparticle tags into 
the liquid media for the sole purpose of facilitating detection.  This is true particularly for 
detection of biochemicals within liquids that are being delivered into a person.  For this 
reason, there is a strong preference to utilize “label-free” detection methods, provided 
that sufficient sensitivity and selectivity are available.  There is also a strong motivation 
to develop detection methods that can provide continuous information at the point of care, 
in order to avoid periodic sampling of fluid from tubing connected to patients, which 
adds a risk of introducing infection and requires tests to be carried out in a separate 
diagnostic laboratory.  Therefore, label-free methods that enable detection of analytes in 
the flow stream using their intrinsic physical properties, such as dielectric permittivity or 
molecular vibrational modes, are most desirable.  Further, label-free detection that would 
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allow a sterile sensor to be placed within the flow stream, but that can be monitored from 
outside the flow stream with a noncontact probing/readout method, is required.  
Therefore, the goal of work in this chapter is to incorporate label-free, non-contact optical 
sensors into the internal surfaces of plastic tubing to enable continuous in-line monitoring 
of the chemical components of the material flowing through the tubing.  A schematic of 
the eventual type of system that could result from the biochemical sensor tubing work is 
shown in Figure 5.1. 
 
Figure 5.1 Schematic representation of how in-line biosensors would be utilized as part of an 
intelligent medical system to measure the contents of IV fluid being delivered to a patient or to 
analyze the contents of a urinary catheter.  The sensors are incorporated into disposable plastic 
tubing and an excitation/readout head clamps around the sensor region. The detection head is 
connected to the instrument through optical fiber connections. 
 
In this chapter, an IV pain medication (promethazine) and a common urinary 
metabolite (urea) were used as model analytes to demonstrate the potential for continuous 
monitoring of an IV delivered drug or kidney function of a patient.  A surface-enhanced 
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Raman scattering (SERS) nanodome structure that is produced upon flexible plastic 
surfaces by a large-area nanoreplica molding process, described in Chapter 4, was used as 
the sensor.  The nanodome structure provides enhancement of the electromagnetic field 
from a laser illumination source to provide an easily measurable SERS spectrum that 
specifically identifies the analyte of interest.  Both separate detection and co-detection of 
promethazine and urea within their clinically relevant concentration ranges, as well as 
kinetic real-time monitoring of changes in analyte concentration, are demonstrated. 
 
5.1.1 Background 
Drug compound – promethazine 
Medication errors occurring either in or out of the hospital are estimated to 
account for 7000 deaths annually, while infusion devices account for up to 35% of errors 
that result in significant harm (Class 4 and 5) [114].  Current “smart” IV medication 
safety systems reduce medication delivery errors by providing standard modular-based 
guidance of the dose and infusion rate through various types of IV administration to the 
clinicians without the use of sensors [115].  Identification and verification of the chemical 
contents of a fluid in an IV line being administered to a patient would provide an 
additional layer of error-checking to ensure that the correct drug and dosage are being 
delivered.   
 Promethazine is part of the phenothiazine chemical class that is used medically as 
an antihistamine, a sedative, and an antiemetic.  The maximum recommended 
concentration for IV administration of promethazine is 25 mg/mL, and overdose can 
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cause severe tissue injury including gangrene, requiring fasciotomy, skin graft, and/or 
amputation [116]. 
 
Metabolite – urea 
Annually, more than 300 million urine analyses are ordered by physicians in the 
United States [117].  Urine tests are very useful as noninvasive diagnosis and evaluation 
of kidney function and health of a patient.  Urea is the main and final product of protein 
metabolism; thus its concentration in urine is used as an indicator of the nutritional status 
of a patient, while its concentration in blood is useful for diagnosis of renal dysfunction.  
During kidney dialysis, urea is recognized as a marker for a wide spectrum of low and 
intermediate-molecular mass toxic solutes that accumulate in patients with diminished 
renal function [118].  Normal physiological levels of urea concentration in blood and 
urine are 2.5 – 6.7 mM and ~ 333 mM, respectively.  In comparison to this normal level, 
the pathophysiological concentration of urea in blood is 30 – 150 mM, which indicates 
lost kidney function due to renal clearance failure [117, 119].  In the case of kidney 
failure, renal replacement therapy in the form of dialysis and transplantation are required 
in order to sustain the life of a patient. 
 The most common method for urea detection is an enzyme-colorimetric approach 
using spectrophotometric detection [120].  However, the colorimetric method involves 
introduction of additional chemicals/enzymes to fluid samples that could potentially harm 
patients, and thus is performed by taking a urine sample to a laboratory for analysis.  In 
addition, reagent mixing and incubation steps required for the colorimetric detection 
make the method unsuitable for real-time monitoring of bodily fluid.   
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 A number of label-free urea sensing methods have been developed including 
enzyme-based field effect transistors (ENFETs); ion sensitive field effect transistors 
(ISFETs); and conductometric, potentiometric and optical fiber sensors [119, 121-126].  
These sensors involve immobilization of a capture probe molecule, urease enzyme, on the 
surface of the gate insulator or the sensor.  However, uncertainties and variations are 
associated with label-free sensors immobilized with enzymes.  These variations are 
caused by interference from ammonia and other ionic substances or by change in solution 
temperature and pH, decreasing the enzyme activity and stability [119].  In addition, 
immobilization methods through cross-linking cause loss of protein flexibility and hinder 
the diffusion of analytes, resulting in the sensor performance (sensitivity, response time) 
being dependent on the method of enzyme immobilization [126].  Therefore, a label-free 
sensor without the requirement for enzyme or probe molecule immobilization is desirable. 
 Infrared (IR) absorption spectroscopy has also been used to detect urea in urine by 
transmitting a selected band of near-IR light through the sample and analyzing the 
resulting spectral information [127].  The IR absorption spectroscopy method does not 
involve probe molecule immobilization and is nondestructive and reagentless, thereby 
permitting in-line identification.  However, due to the relatively high detection limit and 
heterogeneous characteristic of bodily fluid, blood in particular, it is difficult to detect 
urea with sufficient accuracy. 
 
5.1.2 SERS nanodome tubing 
In this chapter, a SERS active surface comprised of an array of closely spaced 
metal nanodomes was incorporated into a plastic flow chamber connected in series with 
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flexible tubing as shown in Figure 5.2.  Figure 5.2b shows a scanning electron 
microscope (SEM) image of the nanodome sensor structure incorporated as the bottom 
surface of the flow cell.  Figure 5.2c shows a finite element method (FEM) simulation of 
the electric field distribution around the nanodomes, in which the greatest 
electromagnetic fields occur in the gaps between adjacent nanodomes.  For SERS 
surfaces to be viable for an application in which they would be used as a single-use 
disposable point-of-care sensor, it is necessary to provide a structure that simultaneously 
provides a large electromagnetic enhancement factor and is made using a low-cost, large-
area manufacturable fabrication method.  The SERS nanodome sensor used in the present 
study provides label-free identification/detection of analytes without having to 
immobilize probe molecules on the sensor surface.  The nanodome surface used in the 
present study is produced on a flexible plastic substrate by a large-area nanoreplica 
molding process to provide peak enhancement factors of 1.37 × 10
8
.  The exemplary 
experiments on the detection of promethazine and urea demonstrate the clinical potential 
for SERS sensors incorporated within biomedical tubing.  The system could enhance 
patient safety through prevention of drug delivery errors that occur by administering an 
incorrect drug or dose, and provide more timely information on the status of a patient 
through monitoring of urinary metabolite concentration. 
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Figure 5.2  (a) Schematic of the biochemical sensor tubing where nanodome sensor structure is 
incorporated as the bottom surface of the flow cell.  (b) SEM image of the nanodome surface.  (c) 3D 
FEM simulation of the electric field distribution (normalized amplitude of the electric field with 
respect to the incident electric field amplitude) displaying regions of enhanced field between adjacent 
nanodomes. 
 
5.2 Materials and Methods 
5.2.1 Nanodome sensor fabrication – nanoreplica molding process 
To produce a template used for the molding, nanoimprint lithography (Molecular 
Imprints) and reactive ion etching were used to pattern an 8-inch (200 mm) diameter 
silicon wafer with a 2-dimensional array of 300 nm diameter holes (period = 400 nm, 
depth = 130 nm), in 8 × 8 mm
2
 dies with overall feature dimensions of 120 × 120 mm
2
.  
Next, a negative volume image of the silicon surface structure was formed by distributing 
liquid UV curable polymer (Gelest) droplets between the silicon wafer and a flexible 
polyethylene terephthalate (PET) sheet.  After curing by exposure to UV light, the 
molded structure was released from the wafer by peeling away the PET, resulting in a 
polymer replica of the silicon wafer structure adhering to the PET sheet.  Then, 100 nm 
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of SiO2 was deposited over the polymer replica by electron beam evaporation, followed 
by deposition of a 200 nm silver thin film, also by electron beam evaporation, to 
complete the device. The cylindrical posts created by the replica molding process evolved 
into rounded dome-like shapes as the deposited films accumulate.  The separation 
distance for the nanodome array was 20 nm with the nanodome base diameter of 380 nm.  
The details of nanodome fabrication using nanoreplica molding process are described in 
Chapter 4. 
 
5.2.2 Flow cell incorporated with nanodome sensor 
The flow cell was made with a stereolithography system (Viper SLA system, 3D 
Systems) using an optically clear resin (WaterClear Ultra 10122, DSM Somos).  The 
dimensions of the flow chamber were 18.5 × 7.5 × 3 mm for length, width, and height, 
respectively.  Inlet/outlet cross sectional dimensions of the flow cell were 3 × 1 mm.  
Two cylindrical openings at the ends of the flow cell were tapped and screwed in with 
polypropylene barbed adapters (10-32 UNF × 1/8 inch ID, Cole-Parmer) connected to 
tubing (1/8 inch ID × 3/16 inch OD, TYGON R-3603).  The nanodome surface was cut 
and attached as the bottom surface of the flow cell using UV-cured adhesive (Addison 
Clear Wave).  The top surface window of the flow cell was sealed by attaching a standard 
No. 2 microscope slide cover glass cut to size using the same UV adhesive. 
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5.2.3 Detection instrument 
The Raman measurement was performed using a 785 nm wavelength diode laser 
system (Ocean Optics) coupled into an optical fiber.  For detection of promethazine, the 
laser power was set to 100 mW.  For detection of urea and urea/promethazine mixture, 
the laser was set to 150 mW.  The laser was focused on the sensor surface by a 10× 
objective lens (NA = 0.28).  SERS photons were collected by the same objective lens, 
into a QE65000 spectrometer (Ocean Optics) using an integration time of 5 sec for all 
experiments. 
 
5.2.4 Experiment procedures 
Experimental procedures were identical for promethazine and urea as well as for 
the promethazine/urea mixture.  For the concentrations series measurement, 
promethazine solution was prepared in DI water at 50, 25, 12.5, 6.25, 3.13, and 1.56 
mg/mL.  Urea solution was prepared in concentrations of 300, 150, 75, 37.5, 18.8, and 
9.38 mM also in DI water.  Urea and promethazine mixture was prepared in three 
different combinations: 300 mM, 25 mg/mL; 150 mM, 25 mg/mL; 300 mM, 12.5 mg/mL 
for urea and promethazine, respectively.  Before the SERS measurement, 5 mL of analyte 
solution was pumped through the sensor tubing manually using a syringe and 
measurements were taken without flow.  After the measurement, the flow cell was 
washed by emptying the analyte solution and flowing through 10 mL of DI water.  
Emptying and rinsing with DI water was repeated three times before introducing another 
analyte with a different concentration.  For statistical significance, measurements on the 
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analyte concentration series were repeated five times (one measurement per analyte 
concentration in a series). 
 For the kinetic on/off measurements, the analyte sample and DI water were 
alternately pumped through the sensor tubing using a separate syringe pump (PHD 
22/2000, Harvard Apparatus) for each solution at 60 sec intervals.  Tubing from the 
syringes containing the sample and blank solution were connected to a three-way 
stopcock valve which was used to alternate the samples flowing into the sensor tubing.  
The solutions were pumped through the tubing at a flow rate of 5 mL/min.  Although 
typical IV injection rates are significantly lower, a flow rate of 5 mL/min was chosen to 
facilitate the kinetic experiment and to minimize cross diffusion of analytes at the 
interface between different solutions as they are being pumped. 
 For comparison, urea detection was performed using a colorimetric urea assay kit 
(DIUR-500, BioAssay Systems).  The same urea samples used for the experiment on 
nanodome sensor tubing were diluted 50-fold in DI water prior to the assay.  Five µL of 
urea sample for each concentration, standard urea solution (50 mg/dL) and DI water 
(blank) were transferred into wells of a clear bottom 96-well plate in triplicates.  Then, 
200 µL of assay reagent mixture included in the kit was added to each well and incubated 
for 20 min at room temperature.  After incubation, a microplate reader (Synergy HT, 
BioTek Instruments) was used to measure the optical density of the samples at 
wavelength of 520 nm. 
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5.2.5 Data analysis 
The background of the raw SERS spectra was removed using a 6th order 
polynomial fit, followed by signal filtering using Savitsky-Golay parameters with smooth 
window of 9 and polynomial order of 3.  The processed spectra were then subtracted by 
the reference spectrum from the blank DI water to obtain the final spectra. 
 
5.3 Results and Discussion 
5.3.1 Detection of promethazine 
Figure 5.3 compares the SERS spectra for promethazine solutions of varying 
concentrations from 3.13 to 50 mg/mL, the range typically delivered to patients.  The 
SERS spectra of promethazine solution exhibited dominant Raman intensity peaks 
located at 1030 cm
-1
, due to the ring-breathing mode of the aromatic rings, and at 1567 
cm
-1
 and 1589 cm
-1
, corresponding to aromatic C=C stretching modes of the molecule 
[128].  Using the dominant peak located at 1030 cm
-1
 for analysis of promethazine, the 
inset shows the plot of the average Raman intensity as a function of promethazine 
concentration with error bars indicating ± 1 standard deviation (N = 5).  A linear fit 
between the Raman intensity at 1030 cm
-1
 and the concentration of promethazine yielded 
an R
2
 value of 0.999.  This demonstrates that the nanodome sensor tubing may be used to 
identify promethazine in solution and the Raman peak magnitude is linearly proportional 
to its concentration. 
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Figure 5.3 SERS spectra for promethazine solution within the sensor tubing. Primary Raman 
intensity peak for promethazine compound corresponding to the ring-breathing mode of the 
aromatic rings can be observed at 1030 cm
-1
. Inset: Raman intensity measured at 1030 cm
-1
 as a 
function of promethazine concentration with error bars indicating ± 1 standard deviation (N = 5). 
 
In order to investigate the real-time detection capability of the nanodome sensor, 
SERS measurements were made with 50 mg/mL promethazine solution and DI water 
alternately pumped through the tubing at 60 sec intervals.  Measurements were taken 
every 5 sec, the same as the integration time of the spectrometer.  Figure 5.4 shows the 
kinetic plot of Raman intensity measured at 1030 cm
-1
 as a function of time.  The results 
indicate that real-time monitoring of solution flowing through tubing can be achieved for 
the nanodome sensors.  Delay in sensor response can be observed due to analyte 
molecules diffusing across a stagnant flow layer that forms near the surface of the 
nanodome sensor as solutions are pumped through the flow cell.  Considering the typical 
injection rate used to administer drugs, the delay in sensor response due to diffusion in 
the stagnant fluid layer should not cause hindrance in detecting medication error before 
any serious health hazard is posed. 
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 From the kinetic plot, the standard deviation (σ) of the Raman signal measured at 
1030 cm
-1
 was 3.51.  Based on the linear dose response curve (inset of Figure 5.3) and 
setting sensor readout resolution as three standard deviations (3σ), the limit of detection 
for nanodome sensors on promethazine was 2.32 mg/mL.  The results suggest that the 
nanodome sensor tubing system is capable of identifying promethazine compounds and 
detecting concentrations that are clinically relevant.  For example, the system could be 
used to detect and prevent hazards associated with IV-delivered promethazine over the 
maximum allowed concentration of 25 mg/mL. 
 
Figure 5.4 Kinetic plot of Raman intensity measured at 1030 cm
-1
 as 50 mg/mL promethazine 
solution and DI water were alternately pumped through the tubing at 60 sec intervals. 
 
5.3.2 Detection of urea 
As with promethazine solution, similar measurements were made for the detection 
of urea solution flowing through the system.  Figure 5.5 compares the SERS spectra for 
urea solutions of varying concentrations from 18.8 to 300 mM, encompassing the range 
typically measured clinically.  Urea solution exhibited a primary Raman intensity peak at 
1000 cm
-1
 from the symmetrical C-N stretch [117].  The inset shows the plot of the 
 91 
average Raman intensity measured at 1000 cm
-1
 as a function of urea concentration with 
error bars indicating ± 1 standard deviation (N = 5).  A linear fit with an R
2
 value of 
0.999 was obtained.  Again, this demonstrates that the nanodome sensor tubing may be 
used to identify urea compound in solution and detect its concentration. 
 
Figure 5.5 SERS spectra for urea solution within the sensor tubing. Primary Raman intensity peak 
for urea corresponding to the symmetrical C-N stretch can be observed at 1000 cm
-1
.  Inset: Raman 
intensity measured at 1000 cm
-1
 as a function of urea concentration with error bars indicating ± 1 
standard deviation (N = 5). 
 
To investigate the real-time detection capability for urea, SERS measurement was 
made with 300 mM urea solution and DI water alternately pumped through the tubing at 
60 sec intervals.  The same integration time and measurement interval as with the 
promethazine experiment were used.  Figure 5.6 shows the kinetic plot of Raman 
intensity measured at 1000 cm
-1
 as a function of time.  Delay in sensor response was 
observed for the urea measurement as well, but it should not cause issues for real-time 
detection. 
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 For urea, the standard deviation (σ) for the Raman intensity at 1000 cm-1 was 2.54.  
Based on the linear dose response curve (inset of Figure 5.5) and three standard deviation 
(3σ) threshold for the sensor readout resolution, the limit of detection for urea was 10.8 
mM.  The results suggest that the nanodome sensor tubing system is capable of 
monitoring kidney activity of a patient through identifying and detecting urea well below 
the typical concentration in urine.  The system could also be used to monitor renal 
clearance failure by detecting urea concentration in blood or dialysate since the detection 
limit of the system is below the pathophysiological concentration of 30 – 150 mM. 
 
Figure 5.6 Kinetic plot of Raman intensity measured at 1000 cm
-1
 as 300 mM urea solution and DI 
water were alternately pumped through the tubing at 60 sec intervals. 
 
To verify the accuracy of the nanodome sensor for detection of urea, a standard 
commercially available colorimetric urea assay kit was also used to measure the 
concentration of urea samples.  Figure 5.7 shows the sensor output comparison between 
the nanodome sensor and the standard colorimetric assay kit.  The comparison data was 
fitted to a xy   curve with an R2 value of 0.990. 
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Figure 5.7 Sensor output comparison for urea concentration detection between nanodome sensor and 
standard colorimetric assay kit. 
 
5.3.3 Detection of urea/promethazine mixture 
The ability for multiplexed detection of analytes is useful as multiple drugs or 
nutrients are often delivered to patients through IV lines in clinical settings.  One 
advantage of SERS-based sensors is their capability for detection of multiple analytes 
simultaneously when the Raman scattered peaks can be individually distinguished.  To 
demonstrate the multiplexed detection capability of the SERS nanodome sensor, mixture 
solutions of urea and promethazine at varying concentrations were introduced into the 
sensor tubing.  Figure 5.8 shows the SERS spectra for the urea and promethazine 
mixtures where primary Raman intensity peaks for both urea and promethazine can be 
observed at 1000 cm
-1
 and 1030 cm
-1
, respectively.  The intensity values for each analyte 
were consistent with measurements made with single analyte solution. 
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Figure 5.8 SERS spectra for urea and promethazine mixture. Primary Raman intensity peaks for 
both urea and promethazine can be observed at 1000 cm
-1





In this chapter, a SERS nanodome sensor chip incorporated in a flow cell was 
used for real-time biochemical sensing of fluid within tubing, and proof-of-concept 
experiments on the label-free detection of urea and promethazine were performed.  The 
potential for an in-line nanodome sensor detection system that would allow real-time 
detection of fluid samples from patients without taking samples and performing 
laboratory based tests was demonstrated.  The technology may be applied to identify drug 
compounds that are being administered to patients for enhanced safety for smart infusion 
systems.  The nanoreplica molding method used to make the nanodome substrates is a 
low-cost, mass-manufacturing process which would allow the devices to be adopted in a 
clinical setting as disposable single-use sensors.  This approach can be further tested by 
detection of additional metabolites and by detection of urinary metabolites within urine 
samples, rather than in buffer as demonstrated in this chapter.  The potential to develop 
 95 
the nanodome sensors fabricated upon thin plastic substrates that are highly flexible can 
also be investigated so that they may be attached to curved surfaces, and incorporated 
directly into the inner surface of cylindrical tubing.  This sensor approach may be applied 
to the internal surface of many types of liquid containers (test tubes, flasks, graduated 
cylinders) for a wide range of applications including but not limited to medical detection, 
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